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Abstract 
Michael John Allingham:  
Novel roles for ICAM1 in leukocyte transendothelial migration. 
(Under the direction of Keith Burridge) 
Leukocyte transendothelial migration (TEM) is a critical regulated step in 
inflammation and is therefore a potential target in the treatment of inflammatory 
diseases.  During TEM, leukocyte -integrins bind to and cluster intracellular 
adhesion molecule-1 (ICAM1) on the surface of the endothelium.  This has been 
shown to initiate signaling in endothelial cells that facilitate leukocyte transmigration.  
In the course of studying the role of ICAM1 in leukocyte TEM, we have discovered 
two signaling pathways that are required for TEM.  First, we found that crosslinking 
of ICAM1 activates Src and Pyk2 tyrosine kinases, which results in tyrosine 
phosphorylation of VE-cadherin on Y658 and Y731.  These phosphorylation events 
require both Src and Pyk2.  Accordingly, inhibition of endothelial Src or Pyk2 
reduced transmigration of leukocytes.  Importantly, expression of Y658F or Y731F 
mutants of VE-cadherin, which cannot be phosphorylated on these residues, also 
inhibits leukocyte TEM demonstrating that VE-cadherin tyrosine phosphorylation is 
required for TEM.  A second set of studies focused on the means by which ICAM1 
might regulate formation of transmigratory cups around adhering leukocytes.  We 
found that exogenously expressed ICAM1 colocalized in dorsal ruffles with the small 
GTPase RhoG and a RhoG-specific exchange factor, SGEF.  Additionally, a proline-
iii
rich region in the ICAM1 cytoplasmic tail directly interacts with the SH3 domain of 
SGEF.  Crosslinking of ICAM1 was observed to activate RhoG in endothelial cells.  
Finally, we found that siRNA-mediated knockdown of SGEF or RhoG inhibited 
formation of transmigratory cups, as well as leukocyte TEM.  In this thesis we 
describe two ICAM1-dependent signaling pathways; one that contributes to 
leukocyte-mediated disassembly of endothelial adherens junctions via VE-cadherin 
phosphorylation, and one that mediates formation of transmigratory cups via 
activation of RhoG.  These signals are required for efficient leukocyte TEM and may 
therefore be suitable targets for anti-inflammatory therapies. 
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Chapter 1: Introduction 
Inflammation occurs in response to diverse types of tissue injury and is 
required for numerous physiologic and pathologic processes.  One of the key 
regulated steps in inflammation is transmigration of leukocytes across the 
endothelium, termed transendothelial migration (TEM).  TEM is a critical component 
of the adaptive and the innate immune responses, which require leukocytes to traffic 
between the bloodstream and both lymphoid tissues and infected tissues.  
Incredibly, it is estimated that, as part of normal immune surveillance, approximately 
5x1011 lymphocytes exit the blood and enter tissues and then return to the 
bloodstream each day (1, 2).   The importance of TEM is clearly demonstrated by a 
family of disorders, termed leukocyte adhesion deficiency (LAD) syndromes, which 
are characterized by mutations in 2 integrins (LAD I), or mutations leading to 
defective glycosylation of selectin ligands (LAD II).  The result of both families of 
mutations is inefficient TEM of neutrophils and monocytes leading to chronic and 
sometimes fatal bacterial infections (3). 
While TEM is vital for normal immune function, when present in excess or in 
an inappropriate location, it can mediate the pathogenesis of numerous disease 
processes.  Increased leukocyte TEM is observed in a host of disorders including 
atherosclerosis, multiple sclerosis, rheumatoid arthritis, psoriasis, and ischemia 
reperfusion injury.  Clearly, improved understanding of how this process is regulated 
2has the potential to contribute to the treatment of numerous inflammatory disorders.  
Additionally, because the endothelium is in continuous contact with the blood, 
endothelial signals that contribute to leukocyte TEM may serve as convenient drug 
targets in the treatment of inflammatory diseases.   
The multistep paradigm of leukocyte TEM divides this process into three 
steps: rolling and adhesion; firm adhesion; and diapedesis (4, 5).  During each of 
these steps, signals are initiated that serve to facilitate progression to the next stage 
of TEM.  During rolling and adhesion, selectins on the endothelial cell establish 
transient weak adhesive interactions with carbohydrate ligands on the leukocyte (6).  
These interactions are responsible for “rolling adhesion” which serves to slow the 
leukocyte in the bloodstream allowing the formation of firm adhesions.  Shortly after 
initial adhesion to the endothelium, leukocytes encounter chemokines displayed on 
the surface of the activated endothelial cell (EC).  These chemokines then activate  
3leukocyte �1 and �2 integrins, facilitating firm adhesion (7, 8).  During firm adhesion, 
the endothelial Ig-family adhesion molecules vascular cell adhesion molecule 1 
(VCAM1) and intercellular adhesion molecule 1 (ICAM1) are engaged by leukocyte 
integrins �4�1 and �L/M�2, respectively.  Engagement of VCAM1 and ICAM1 in turn 
initiates diverse signals within the EC which are required for diapedesis (9, 10).  
Diapedesis appears to require two additional adhesion molecules, PECAM and 
CD99, which are expressed on both leukocytes and endothelial cells (11).  Despite a 
well accepted role in diapedesis, the exact function of PECAM and CD99 in this 
process remains unclear.  Leukocytes undergoing diapedesis utilize one of two 
pathways; the paracellular, which occurs between adjacent ECs, or the transcellular, 
which occurs through a pore formed in the body of the endothelial cell (12).  Most 
studies have found that paracellular migration of leukocytes accounts for the majority 
of leukocyte TEM (12-15).  
In the last decade, the number of endothelial signaling pathways implicated in 
mediating TEM has grown substantially.  Interestingly, many of these signals are 
initiated by leukocyte adhesion to proteins expressed on the surface of the 
endothelium and impact directly or indirectly on endothelial cell-cell junctions.  The 
potential interplay between transcellular and paracellular transmigration is an 
exciting area of study and is discussed in the future directions section.  However, 
what follows is a discussion focused primarily on the mechanisms by which 
leukocyte adhesion to ECs results in signals that affect endothelial cell-cell junctions 
during paracellular leukocyte transmigration. 
4Endothelial cell-cell junctions in leukocyte TEM 
 
Adherens junctions 
In most endothelial beds, paracellular leukocyte TEM is regulated in large part 
by the endothelial adherens junction.  The major adhesive component of the 
adherens junction is vascular endothelial cadherin (VE-cadherin), a calcium-
dependent, homophilic cell-cell adhesion molecule.   Similar to other cadherins, VE-
cadherin is linked to the actin cytoskeleton via members of the catenin family.  �-
catenin binds directly to the cytoplasmic tail of VE-cadherin and is itself bound by �-
catenin.  �-catenin interacts with F-actin as well as the actin binding proteins �-
actinin, vinculin, and AF6 (16).  It should be noted that recent studies of E-cadherin, 
which shares many of the same properties as VE-cadherin, indicate that the exact 
nature of the cadherin-catenin-actin complex is more complicated than previously 
thought.  Specifically, a stable cadherin-�-catenin-�-catenin-F-actin tetramer does 
not appear to exist in cells (17).  Rather, monomeric �-catenin can bind to cadherins 
via �-catenin or it can bind to F-actin as a homodimer where it inhibits Arp2/3 
dependent actin polymerization (18).  These new insights into the nature of the 
adherens junction may have implications on the regulation of junctional integrity, and 
therefore on regulation of leukocyte TEM.   
In addition to �- and �-catenin, VE-cadherin binds, via its juxtamembrane 
region, to p120 catenin.  This interaction modulates cadherin adhesion and has been 
shown to play a role in keeping VE-cadherin at the cell membrane, as well as 
5regulating the protein levels of cadherins in the cell (19-21).  Of particular note, 
recent work has demonstrated that the interaction of p120 catenin with VE-cadherin 
inhibits the clathrin-dependent endocytosis of VE-cadherin (22).   
That VE-cadherin is a critical regulator of the leukocyte TEM is demonstrated 
by several in vitro and in vivo studies wherein treatment of ECs with blocking anti-
VE-cadherin antibodies caused increased TEM and loss of endothelial barrier 
integrity (23-27).  Interestingly, leukocytes themselves induce transient displacement 
of VE-cadherin from cell-cell junctions during paracellular passage across the 
endothelium (15, 28, 29).  In addition, a recent study demonstrated that IL-1�
treatment of ECs disrupted adherens junctions, resulting in monocytes 
transmigrating by a predominantly paracellular route (13).  Thus, the adherens 
junction may be a critical regulator of the mode of leukocyte TEM.  Specifically, VE-
cadherin may be an important target in the signaling pathways that mediate 
paracellular migration of leukocytes.   
 
Tight junctions 
While tight junctions are not thought to contribute significantly to the regulation of 
leukocyte TEM in high endothelial venules, they do appear to play a role in the case 
of TEM in the brain (30). In the endothelium comprising the blood-brain barrier 
(BBB), tight junctions (TJ) composed of the transmembrane proteins occludin, 
junctional adhesion molecules (JAMs) and claudins are located apically and serve to 
restrict passage of fluid and macromolecules across the BBB.  Zonula occludens 
family proteins, ZO-1, -2, and -3, bind to the intracellular tail of occludin and serve as 
6scaffolds for a variety of other proteins (31).  Of note, the interaction between 
occludin and ZO-1 has been shown to be critical for the TJ integrity (32).  In contrast 
to endothelia elsewhere in the body, ECs comprising the BBB have well-defined tight 
junctions that are observed to be disassembled under conditions of 
neuroinflammation (28, 33).  Moreover, there is evidence that TJs are capable of 
exerting regulatory control of leukocyte TEM (34).  However, to date, there has been 
far less study of the role of TJs in regulation of leukocyte TEM. 
 
Regulation of endothelial cell-cell junctions during leukocyte TEM: roles of 
adhesion molecule signaling. 
 
In order to cross the endothelium, leukocytes transmigrating via the paracellular 
pathway require endothelial cells to transiently disassemble their junctions.  There 
have been several hypotheses advanced to explain how junctional disassembly is 
achieved.  These include degradation of endothelial junctional proteins by leukocyte 
proteases (29, 35), “dilution” membranes containing junctional proteins (36), or 
removal perhaps by endocytosis.  It is possible that a combination of these 
processes is responsible, with different types of endothelial cells and leukocytes 
utilizing different combinations.  The potential roles of proteases (9, 37) and dilution 
(36) are discussed in recent reviews.  Here we will focus on how signals initiated by 
leukocyte interactions with ECs during rolling and firm adhesion may weaken 
endothelial cell-cell junctions and mediate paracellular TEM.   
 
7SELECTINS  
E-selectin and P-selectin are both endothelial selectins which become 
upregulated under inflammatory conditions.  E-selectin expression is activated by 
inflammatory mediators such as TNF and IL-1 while the P-selectin protein is 
stored in intracellular vesicles called Weibel-Palade Bodies which fuse with the 
plasma membrane in response to stiumuli such as thrombin or histamine (38-41).  
While the selectins are most frequently discussed in terms of their ability to support 
rolling adhesion of leukocytes in the early stages of TEM, there is also ample 
evidence, from antibody crosslinking studies, that selectins are capable of 
generating outside-in signals.  For example, both E- and P-selectin crosslinking has 
been associated with increases in intracellular free calcium (42).  Release of 
cytoplasmic calcium is one means by which tension is generated in ECs and 
depends on activation of calmodulin, resulting in phosphorylation of myosin light 
chain (MLC).  Phosphorylated MLC binds actin leading to acto-myosin contraction 
which has been hypothesized to contribute to junctional disruption by pulling 
adjacent endothelial cells apart (43-45).  The fact that E-selectin, P-selectin, VCAM1 
and ICAM1 are all capable of increasing intracellular calcium in ECs is strongly 
suggestive of a role for this pathway in mediating TEM (42, 46).  In support of this, 
inhibition of calcium signaling in ECs resulted in decreased TEM of T-lymphocytes 
(46). 
Other studies have shown that leukocyte adhesion, or E-selectin crosslinking 
resulted in activation of the mitogen-activated kinase pathway (47).  Another study 
found that E-selectin engagement during tumor cell TEM resulted in activation of p38 
8MAPK and ERK leading to stress fiber formation and, interestingly, Src kinase 
activation which induced dissociation of VE-cadherin and -catenin (48).  Thus, E-
selectin may be capable of generating tension on junctions as well as 
downregulating junctional integrity.  It is therefore attractive to hypothesize that 
leukocyte clustering of E-selectin may contribute to junctional disruption at sites of 
leukocyte (and tumor cell) paracellular transmigration.  Signaling of E-selectin during 
leukocyte TEM are summarized in Figure 2.  Certainly, further investigation of this 
possibility is warranted. 
 
VCAM1 
VCAM1, while not expressed in resting endothelial cells, is induced in 
inflamed endothelium where it acts as a ligand for leukocyte 1 integrins.  Like the 
selectins, VCAM1 can contribute to the rolling adhesion of leukocytes.  In addition, 
VCAM1 has a role in the firm adhesion of leukocytes.  Interestingly, VCAM1 was 
recently observed in leukocyte docking structures, which are cup-like actin-based 
membranous protrusions which partially engulf transmigrating leukocytes (49).  
These structures are thought to be required for efficient leukocyte TEM (12).  Like 
other endothelial adhesion molecules, VCAM1 clustering generates diverse signals 
in ECs which are thought to facilitate transmigration of leukocytes.   
One important function of VCAM1 is regulation of Rho family GTPases during 
leukocyte TEM.  In studies examining the effects of Rho and Rac on endothelial 
junctions, it was observed that transduction of HUVEC with a constitutively active 
RacV12 mutant results in Rho-dependent stress fiber formation as well as in ROS-
9dependent loss of VE-cadherin from cell-cell junctions (50).  Interestingly, 
transduction of the corresponding active Rho mutant, RhoV14, did not disrupt cell-
cell contacts.  This suggests that, while Rho-mediated contractility plays a role in 
mediating TEM, it is not itself sufficient for generation of large intercellular gaps. It 
was subsequently shown that VCAM-1 crosslinking resulted in a phenotype similar 
to that seen when RacV12 was expressed (51).  Crosslinking of VCAM in HUVEC 
resulted in activation of Rac and was associated with generation of stress fibers as 
well as gaps between endothelial cells (Figure 2) (51).  These responses were 
accompanied by a reduction in transendothelial resistance and were found to be 
dependent on Rho, Rac, ROS, and p38 MAPK.  It is worth noting that large gaps 
between cells are not seen during leukocyte TEM except in cases where leukocytes 
greatly outnumber ECs (52).  These VCAM1-mediated gaps may result from the 
crosslinking of VCAM1 all over the EC surface, which results in greatly amplified 
global VCAM1 signaling in the cell.     
Interestingly, disrupted -catenin staining was observed when VCAM-1 was 
crosslinked.  Subsequently, van Buul and colleagues found that Rac mediated ROS 
formation resulted in activation of Pyk2 (53).  Pyk2 was then observed to localize to 
cell-cell junctions where it phosphorylated -catenin (53).  Inhibition of Pyk2 
prevented junctional disruption of cell-cell junctions by VE-cadherin blocking 
antibodies.  Thus, it is attractive to envision a pathway wherein VCAM1 engagement 
activates Rac leading to generation of ROS and subsequent Pyk2 mediated 
phosphorylation of -catenin and accompanied junctional disruption.  
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ICAM1  
ICAM1 has several functions in transmigration that overlap with those of 
VCAM1.  Both proteins are found in leukocyte docking structures, and both are 
known to facilitate leukocyte firm adhesion.  Additionally, ICAM1 and VCAM1 both 
regulate the activity of Rho family GTPases and may induce tyrosine 
phosphorylation of components of cell-cell junctions.  As previously discussed, 
during transmigration, leukocytes are partially engulfed by an endothelial docking 
structure also called a transmigratory cup (12, 49, 54).  This structure is highly 
enriched in ICAM1 and may serve as a means of generating local signals important 
for TEM.  Leukocyte binding to and clustering of endothelial ICAM1 has been shown 
to transduce outside-in signals within ECs; these signals are required for efficient 
transmigration (10).  Expression of an ICAM1 mutant lacking its cytoplasmic tail 
inhibits T-lymphocyte transmigration across brain endothelial monolayers (55).  
Moreover, antibody-blockade of endothelial ICAM1 inhibits leukocyte-mediated 
junctional disassembly, suggesting that ICAM1 signaling is required for paracellular 
transmigration of leukocytes (15, 28).  
Antibody crosslinking studies with ICAM1 have led to the discovery of signals 
resulting in tyrosine phosphorylation of several endothelial proteins.  Phosphorylated 
proteins include Src, Pyk2, FAK, cortactin, paxillin, p130Cas, ezrin and, now, VE-
cadherin (56-59).  Interestingly, several of these phosphorylation events have been 
shown to be involved in regulation of paracellular leukocyte TEM.  For example, 
numerous lines of evidence have demonstrated that tyrosine phosphorylation of AJ 
proteins, such as VE-cadherin and �-catenin, is associated with the disassembly of 
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junctions (60-63).  Work presented in this thesis has demonstrated that ICAM1 
engagement leads to phosphorylation of VE-cadherin on tyrosines 658 and 731.  
These phosphorylation events required the activities of both Src and Pyk2 tyrosine 
kinases, and expression of VE-cadherin mutants lacking these tyrosine residues 
inhibited neutrophil TEM.  ICAM1-mediated phosphorylation of VE-cadherin 
specifically on Y658 and Y731 may cause junctional disassembly by two potential 
mechanisms.  Previous work demonstrated that the phosphomimetic VE-cadherin 
mutant, Y731E, exhibits greatly decreased binding to -catenin (64).  Thus, 
phosphorylation on this residue would lead to uncoupling of VE-cadherin from the 
actin cytoskeleton, thereby weakening junctions and promoting leukocyte passage 
through the paracellular pathway.  Similar experiments with the Y658E VE-cadherin 
mutant demonstrated that phosphorylation of Y658 reduces binding to p120-catenin 
(64).  Since it has been shown that interaction with p120-catenin stabilizes VE-
caderin at the junctions by preventing its clathrin-mediated endocytosis, the loss of 
p120-catenin binding may remove VE-cadherin from sites of paracellular TEM by an 
endocytic mechanism (19, 22).  Given mounting evidence that tyrosine 
phosphorylation of junctional proteins regulates junctional integrity during leukocyte 
TEM, it will be interesting in the future to determine whether ICAM, or other adhesion 
receptors, are capable of mediating the phosphorylation of other components of the 
AJ or TJ. 
Another signal recently shown to play a role in paracellular leukocyte TEM is 
ICAM1-mediated Src-dependent tyrosine phosphorylation of cortactin (59, 65).  
While the means by which ICAM1 activates Src is not clearly understood, it is known 
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that activation of Src requires xanthine oxidase and the phosphatase SHP2 (58).  
Recently, Yang and colleagues convincingly demonstrated a requirement for Src-
mediated phosphorylation of cortactin specifically in paracellular leukocyte TEM (59, 
65).  They show that cortactin phosphorylation is required for leukocyte-mediated 
cytoskeletal remodeling in ECs as well as for clustering of ICAM1.  During, TEM, 
ICAM1 clustering is required for numerous signaling processes in ECs, thus the Src-
cortactin pathway may function upstream of numerous other ICAM1-dependent 
signals (59). 
Another means by which ICAM1 may regulate cell-cell junctions is via its 
ability to stimulate contractility in the EC.  It has been widely hypothesized that 
generation of tension in ECs may contribute to junctional disassembly and thus 
passage of leukocytes through the endothelium via the paracellular pathway.  
ICAM1, like VCAM1, has also been shown to regulate Rho family GTPases during 
leukocyte TEM.  Crosslinking of ICAM1 has been shown to activate RhoA in 
endothelial cells resulting in stress fiber formation (66).  In addition, ICAM1 
crosslinking has been shown to induce increases in intracellular free calcium, which 
as previously discussed may contribute to acto-myosin contraction in the cell (67-
69).  Moreover, endothelial-specific myosin light chain kinase (EC MLCK) also 
appears to be regulated by Src-mediated tyrosine phosphorylation (70, 71).  This 
regulation is facilitated by stable association of a pool of EC MLCK with cortactin and 
Src (70, 71).  These data raise the question whether Src activated downstream from 
ICAM1 may also activate EC MLCK leading to cellular contractility and intracellular 
gap formation which has been associated with enhanced leukocyte diapedesis (43-
13
45).  Thus, ICAM1 generates multiple signals capable of increasing tension in ECs.  
Such signals may collaborate with signals that weaken cell-cell junctions, such as 
tyrosine phosphorylation, to open gaps between ECs allowing leukocyte passage 
across the endothelium.  A summary of ICAM1-mediated signals that may disrupt 
AJs can be found in Figure 2. 
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PECAM and CD99  
PECAM and CD99 are localized to cell-cell junctions in confluent ECs (36).  
Similarly, both are expressed on leukocytes and ECs and are capable of homophilic 
interaction.  Unlike ICAM1 or VCAM1, signaling functions for these molecules during 
TEM have not been well characterized, however they are required for efficient TEM 
of leukocytes in vitro.  Blockade of PECAM or CD99 specifically inhibits 
transmigration of leukocytes at the stage of diapedesis.  Interestingly, while blockade 
of PECAM arrests leukocytes on the surface of ECs above cell-cell junctions, 
blockade of CD99 was shown to trap neutrophils in the space between adjacent 
endothelial cells (11).  Equal effects were observed whether blocking antibodies 
were applied to leukocytes or ECs, strongly suggesting homophilic interactions 
during TEM.  Blockade of PECAM and CD99 was additive in their inhibition of 
neutrophil TEM, indicating that PECAM and CD99 likely function sequentially during 
diapedesis (11).  While these molecules are clearly required for TEM, their exact role 
remains somewhat unclear.  They are not required for adhesion of leukocytes to 
ECs under static or shear flow conditions, nor do they appear to be required for 
leukocytes to “find” cell-cell junctions.  One potential function of PECAM and or 
CD99 is suggested by the observation that endothelial barrier function is maintained 
in the face of substantial leukocyte traffic across the endothelium (45, 52).  The 
function of PECAM or CD99 may be to substitute for components of the AJ and TJ, 
which traditionally maintain endothelial barrier function, but which are displaced from 
sites of leukocyte TEM.  Because both PECAM and CD99 are expressed on both 
leukocytes and ECs, homophilic interactions between PECAM and CD99 could 
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maintain a seal around transmigrating leukocytes.  With this in mind, it is intriguing to 
note that, similar to junctional proteins such as VE-cadherin and occludin, the 
cytoplasmic domain of PECAM is able to interact with the actin or intermediate 
filament cytoskeleton via - and -catenins (72).  It is also interesting to note that 
specialized vesicles containing PECAM are seen to fuse with the membrane at sites 
of leukocyte transmigration; thus endothelial PECAM is specifically concentrated at 
the correct time and place to interact with leukocytes as they cross the endothelium 
(73).  Clearly, further study is needed to examine potential signals generated by 
these proteins during TEM.  Additionally, the roles of homophilic interactions 
between leukocytes and ECs via CD99 and PECAM are extremely intriguing and 
worthy of future investigations.  
 
JAMs 
The JAM family is composed of three members, A, B and C, and are all expressed in 
ECs and are localized to cell-cell junctions (74-78).  JAM-A and JAM-C are also 
expressed on numerous leukocyte types (79-81).  JAM family molecules are all 
bound by both integrins and other JAM family members.  Specifically, JAM-A is a 
ligand for LFA-1, while JAM-B is bound by VLA-4 and JAM-C is bound by MAC-1 
and X2 (82-84).  JAM-A can engage in homophilic interactions, while JAM-B and 
JAM-C appear to bind one another.  Based on antibody blocking studies, all three 
isotypes appear to play a role in leukocyte transmigration, although much remains 
unknown (78, 85-88).  However, a recent report demonstrated that knockdown of 
JAM-C resulted in reduced basal permeability as well as inhibited in vitro and in vivo 
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increases in permeability induced by histamine and vascular endothelial growth 
factor (VEGF).  JAM-C was seen to regulate both actomyosin contraction as well as 
the integrity of VE-cadherin based junctions.  The latter function was dependent on 
the small GTPase Rap1, which has previously been shown to play a role in 
regulation of leukocyte TEM (89).  In this study, it was observed that increased Rap1 
activity stabilized endothelial adherens junctions as well as inhibited transmigration 
of leukocytes.  Thus, while a specific means of regulating Rap1 during TEM has not 
yet been elucidated, perhaps one or more JAM family proteins serve this function. 
While it is clear that endothelial junctions are important regulators of leukocyte 
transmigration, the roles of many endothelial adhesion molecules in regulation of cell 
junctions remain unclear.  These molecules and their downstream signals are 
attractive targets for therapeutic intervention in the treatment of inflammatory 
disorders.  Accordingly, my thesis has centered specifically on the endothelial 
adhesion molecule ICAM1.  The next two chapters detail two lines of inquiry focused 
on the signals generated by ICAM1 during leukocyte transendothelial migration.  The 
final chapter presents my ideas for future studies that could build on this work.  
 
Chapter 2: ICAM1-mediated, Src- and Pyk2-dependent VE-cadherin tyrosine 
phosphorylation is required for leukocyte transendothelial migration 
Summary 
Leukocyte transendothelial migration (TEM) has been modeled as a multistep 
process beginning with rolling adhesion, followed by firm adhesion, and ending with 
either transcellular or paracellular passage of the leukocyte across the endothelial 
monolayer.  In the case of paracellular TEM, endothelial cell (EC) junctions are 
transiently disassembled to allow passage of leukocytes.  Numerous lines of 
evidence demonstrate that tyrosine phosphorylation of adherens junction proteins, 
such as vascular endothelial cadherin (VE-cadherin) and �-catenin, correlates with 
the disassembly of junctions.  However, the role of tyrosine phosphorylation in the 
regulation of junctions during leukocyte TEM is not completely understood.  Using 
human leukocytes and ECs, we show that ICAM1 engagement leads to activation of 
two tyrosine kinases, Src and Pyk2.  Using phosphospecific antibodies, we show 
that engagement of ICAM1 induces phosphorylation of VE-cadherin on tyrosines 
658 and 731, which correspond to the p120-catenin and -catenin binding sites, 
respectively.  These phosphorylation events require the activity of both Src and 
Pyk2.  We find that inhibition of endothelial Src with PP2 or SU6656 blocks 
neutrophil transmigration (71.1% +/- 3.8, and 48.6 +/- 3.8% reduction, respectively) 
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while inhibition of endothelial Pyk2 also results in decreased neutrophil 
transmigration (25.5 +/-6.0 reduction).  Moreover, overexpression of the non-
phosphorylatable Y658F or Y731F mutants of VE-cadherin impairs transmigration of 
neutrophils compared with overexpression of wild type VE-cadherin (32.7% +/-7.1, 
and 38.8 +/-6.5 reduction, respectively).  Our results demonstrate that engagement 
of ICAM1 by leukocytes results in tyrosine phosphorylation of VE-cadherin, which is 
required for efficient neutrophil transendothelial migration.   
 
Introduction 
Inflammation is a component of the normal immune response in which 
leukocytes leave the bloodstream and pass into tissues to fight infection.  However, 
when dysregulated, inflammation contributes to numerous disease processes. 
Passage of leukocytes across the endothelium and into tissues, termed 
transendothelial migration (TEM), is a critical component of the inflammatory 
response.  The multistep paradigm of leukocyte TEM divides this process into three 
steps: rolling and adhesion; firm adhesion; and diapedesis (4, 5).  During each of 
these steps, signals are initiated that serve to facilitate progression to the next stage 
of TEM.  During rolling and adhesion, selectins on the endothelial cell establish 
transient weak adhesive interactions with carbohydrate ligands on the leukocyte (6).  
At this time leukocytes encounter chemokines displayed on the surface of the 
activated endothelial cell (EC).  These chemokines then activate leukocyte �1 and �2
integrins, facilitating firm adhesion (7, 8).  During firm adhesion, the endothelial Ig-
family adhesion molecules VCAM1 and ICAM1 are engaged by leukocyte integrins 
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�4�1 and �L/M�2, respectively.  Engagement of VCAM1 and ICAM1 in turn initiates 
diverse signals within the EC which are required for diapedesis (9, 10).  Leukocytes 
undergoing diapedesis utilize one of two pathways; the paracellular, which occurs 
between adjacent ECs, or the transcellular, which occurs through a pore formed in 
the body of the endothelial cell (12).  However, the factors that influence the relative 
utilization of these two pathways have not yet been fully characterized. 
Paracellular leukocyte TEM is regulated in large part by the endothelial 
adherens junction.  The major adhesive component of the adherens junction is 
vascular endothelial cadherin (VE-cadherin), a calcium-dependent, homophilic cell-
cell adhesion molecule.  That VE-cadherin is a critical regulator of the leukocyte 
TEM is demonstrated by studies in which treatment of ECs with blocking anti-VE-
cadherin antibodies caused increased TEM and loss of endothelial barrier integrity 
(23, 24, 26).  Interestingly, leukocytes themselves induce transient displacement of 
VE-cadherin from cell-cell junctions during paracellular passage across the 
endothelium (15, 26, 28).  In addition, IL-1� treatment of ECs disrupted adherens 
junctions, resulting in monocytes transmigrating by a predominantly paracellular 
route (13).  Thus, the adherens junction may be a critical regulator of the mode of 
leukocyte TEM.  Specifically, VE-cadherin may be an important target in the 
signaling pathways that mediate paracellular transmigration of leukocytes.   
Numerous lines of evidence have demonstrated that tyrosine phosphorylation 
of endothelial adherens junction proteins is associated with the dissociation of 
junctions (60-63).  While much is known about the role of tyrosine phosphorylation in 
regulating the general maintenance of adherens junctions in endothelia, the role of 
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tyrosine phosphorylation of EC adherens junction proteins as it relates specifically to 
leukocyte TEM has not been fully explored.  Interestingly, it has been shown that 
engagement of ICAM1 and VCAM1 generates diverse outside-in signals, which are 
required for leukocyte TEM (9, 10).  Prominent among these signals is the activation 
of cellular kinases resulting in tyrosine phosphorylation of several proteins (56-58, 
65). 
We tested the hypothesis that signals initiated by leukocyte adhesion could 
induce tyrosine phosphorylation of adherens junction proteins within the EC.  We 
show that coincubation of leukocytes with TNF-treated ECs enhances tyrosine 
phosphorylation of VE-cadherin, specifically on residues Y658 and Y731.  
Furthermore, we observe that while ICAM1 is widely distributed across the apical 
surface of ECs, it is significantly enriched near cell-cell junctions.  We therefore 
tested the role of ICAM1-mediated signaling in leukocyte-mediated VE-cadherin 
phosphorylation and found that engagement of ICAM1 is sufficient to induce tyrosine 
phosphorylation of VE-cadherin on tyrosines 658 and 731.  In agreement with 
previous studies, we find that ICAM1 engagement enhances the activity of Src 
kinase (56, 58).  Additionally, we have demonstrated for the first time that ICAM1 
engagement results in activation of endothelial Proline-rich tyrosine kinase 2 (Pyk2).  
Moreover, ICAM1 is capable of recruiting the active forms of both kinases to sites of 
ICAM1 engagement.  Accordingly, inhibition of Src or Pyk2 decreases ICAM1-
mediated VE-cadherin phosphorylation.  Finally, we show that activation of 
endothelial Src and Pyk2, as well as VE-cadherin phosphorylation on Y658 and 
Y731 are all required for efficient transendothelial migration of neutrophils.  These 
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data represent the first direct evidence that endothelial Pyk2 and VE-cadherin 
phosphorylation play a role in mediating leukocyte TEM.    
 
Results 
Leukocyte adhesion to endothelial cells induces tyrosine phosphorylation of VE-
cadherin 
Previously, it was reported that coincubation of ECs and C5a-activated 
neutrophils causes increased tyrosine phosphorylation of AJ proteins, however, the 
specific mechanisms of leukocyte-induced modification of AJ proteins remain 
unclear (90, 91).  To examine specifically the consequences of leukocyte binding to 
ECs on the phosphorylation of VE-cadherin, we treated endothelial cells with TNF�,
which has been shown to increase expression of cell adhesion molecules such as 
ICAM1 and VCAM1 (92).  We then incubated ECs with monocytic THP-1 cells.  
THP-1 cells were used in order to avoid inflammatory factors released by activated 
neutrophils as well as degradation of VE-cadherin by neutrophil proteases during 
sample preparation as has been previously described (93).  After coincubation with 
THP-1 cells, samples were lysed in gel sample buffer and boiled to inactivate cellular 
proteases, kinases and phosphatases, and then diluted to allow immunoprecipitation 
with anti-phosphotyrosine antibodies.  To determine the amount of tyrosine 
phosphorylated VE-cadherin, immunoprecipitates were analyzed by western blot 
using anti-VE-cadherin antibody.  Interestingly, we observed that THP-1 adhesion 
resulted in an increase in VE-cadherin tyrosine phosphorylation (Figure 3A).  
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We next wished to determine specific residues on VE-cadherin that may be 
phosphorylated upon leukocyte adhesion.  We therefore took advantage of newly 
available phosphospecific antibodies directed against VE-cadherin phosphorylated 
on either Y658 or Y731.  TNF-treated ECs were again incubated with THP-1 cells 
for various times and were then lysed directly in sample buffer.  Lysates were then 
analyzed by western blot using phosphospecific anti-VE-cadherin antibodies.  
Incubation of ECs with THP-1 cells for 10 minutes increased tyrosine 
phosphorylation of VE-cadherin at both tyrosine residues, demonstrating that 
adhesive interactions between leukocytes and ECs are capable of mediating 
tyrosine phosphorylation of VE-cadherin (Figure 3B). 
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ICAM1 localizes to cell-cell junctions in TNF"-treated ECs where ICAM1 
engagement increases local tyrosine phosphorylation  
 We hypothesized that molecules involved in the firm adhesion of leukocytes, 
such as ICAM1, could signal to endothelial cell-cell junctions during leukocyte TEM.  
To examine the localization of ICAM1 relative to cell junctions, we stained ICAM1 
and VE-cadherin in TNF�-treated ECs.  In agreement with previous reports, we 
found that ICAM1 is enriched at sites of cell-cell contact (Figure 4A) (14, 94).  
Previously, ICAM1 engagement has been shown to induce tyrosine phosphorylation 
of several molecules (56-58, 65).  To specifically examine signals within ECs, we 
used anti-ICAM1 antibody-coated polystyrene beads to crosslink ICAM1 on TNF�-
treated ECs as described in Materials and Methods.  We then examined 
phosphotyrosine localization by immunofluorescence and observed that 
phosphotyrosine staining was increased specifically at sites where anti-ICAM1 
beads adhered.  Thus, ICAM1 engagement induces a local increase in 
phosphotyrosine (Figure 4B).  
The importance of ICAM1 in TEM and the observation that ICAM1 
engagement leads to local increases in tyrosine phosphorylation led us to test 
whether increased tyrosine phosphorylation of AJ proteins would increase leukocyte 
TEM. Pervanadate treatment of ECs has previously been shown to increase tyrosine 
phosphorylation of AJ proteins as well as increasing neutrophil TEM (61, 63).  We 
confirmed these findings in our system as well (data not shown).  This suggests that 
tyrosine phosphorylation of AJ proteins may indeed be important in regulating 
leukocyte TEM.  
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ICAM1 engagement results in tyrosine phosphorylation of VE-cadherin 
The observation that ICAM1 localizes to cell-cell junctions and that ICAM1 
engagement increases localized phosphotyrosine levels led us to examine whether 
ICAM1 signaling plays a role in leukocyte-mediated tyrosine phosphorylation of VE-
cadherin.  In order to specifically activate ICAM1-mediated signals, beads coated 
with anti-ICAM1 antibody or with control IgG were added to TNF�-treated ECs and 
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anti-phosphotyrosine immunoprecipitations were performed followed by western blot 
analysis with anti-VE-cadherin antibodies as before. Incubation of cells with anti-
ICAM1 beads, but not control IgG beads, caused an increase in VE-cadherin 
phosphorylation (Figure 5A). 
The observation that ICAM1 engagement leads to tyrosine phosphorylation of 
VE-cadherin led us to examine whether leukocyte binding to ICAM1 is the only 
signal that regulates tyrosine phosphorylation of VE-cadherin.  To test this, we 
pretreated ECs with blocking anti-ICAM1 antibodies, and coincubated these ECs 
with THP-1 cells and assayed for VE-cadherin phosphorylation as before. To our 
surprise, blocking ICAM1 did not significantly inhibit VE-cadherin phosphorylation 
(data not shown).  This led us to test whether other signals might contribute to the 
tyrosine phosphorylation of VE-cadherin during THP-1 adhesion.  Because 
monocytic cells such as THP-1 also bind VCAM1, which is known to generate 
signals in endothelial cells, we asked whether VCAM1 might also mediate tyrosine 
phosphorylation of VE-cadherin.  To test this, we crosslinked VCAM1 using anti-
VCAM1 beads and assayed for VE-cadherin phosphorylation as before.  
Interestingly, we found that VCAM1 is also capable of inducing tyrosine 
phosphorylation of VE-cadherin (Figure 6).  To avoid effects due to VCAM1 
signaling, we coincubated ECs with granulocytic HL-60 cells which, in contrast to 
THP-1 cells, do not express the VCAM1-binding integrin VLA-4 (95).  When we 
assayed for VE-cadherin phosphorylation, we found that adhesion of HL-60 cells 
induced robust phosphorylation of VE-cadherin.  This was completely blocked by 
pretreatment of ECs with ICAM1 blocking antibodies (Figure 5B). 
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We next examined which VE-cadherin residues became tyrosine 
phosphorylated downstream from ICAM1 engagement. TNF�-treated ECs were 
incubated with anti-ICAM1 beads for various times and cells were lysed directly in 
sample buffer.  Samples were then analyzed by western blot using phosphospecific 
antibodies directed against VE-cadherin phosphorylated on either tyrosine 658 or 
731.   After ten minutes, maximal tyrosine phosphorylation was seen at both tyrosine 
residues (Figure 5C).  By thirty minutes, levels of tyrosine phosphorylation had 
declined to near baseline levels (Figure 7).  These data indicate that ICAM1-
mediated signals can induce VE-cadherin tyrosine phosphorylation and thus may be 
responsible for leukocyte-induced VE-cadherin phosphorylation. 
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Activated Src is recruited to sites of ICAM1 engagement 
We next wanted to dissect the signaling pathways by which ICAM1 clustering 
leads to VE-cadherin phosphorylation.  ICAM1 engagement has previously been 
shown to activate Src family kinases resulting in tyrosine phosphorylation of several 
proteins (56-58).  In support of these findings, incubation of ECs with anti-ICAM1 
beads resulted in an increase in Src phosphorylated on Y418, a phosphorylation 
event which has been shown to be critical for activation of the kinase (Figure 8A).  
To explore whether activated Src kinase would be recruited to sites of ICAM1 
engagement, ECs were incubated with anti-ICAM1 beads, then fixed and stained for 
Src pY418.  We observed that activated Src was strongly recruited to sites of ICAM1 
engagement.  By contrast, control beads coated with mouse IgG did not recruit Src 
(Figure 8B).  To test the specificity of ICAM1 recruitment of active Src, ECs were 
incubated with anti-ICAM1 beads and stained for Src pY418 or the control proteins, 
�-catenin or VE-cadherin.  Positive staining at sites of bead adhesion was quantified, 
revealing that ICAM1 engagement did not recruit �-catenin or VE-cadherin (Figure 
8C).  Thus, activated Src is specifically recruited to sites of ICAM1 engagement.   
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ICAM1 engagement activates endothelial Pyk2 
Previous work has shown that Proline-rich tyrosine kinase 2 (Pyk2) plays a 
role in junctional disassembly and localizes to cell-cell junctions upon junctional 
disruption (53).  Thus, Pyk2 is a candidate tyrosine kinase downstream from ICAM1.  
To test whether ICAM1 can activate Pyk2, we used a phosphospecific antibody 
directed against pY402 of Pyk2, which is the autophosphorylation site for Pyk2.  
Again, control or anti-ICAM1 beads were added to TNF�-treated ECs for ten 
minutes, followed by lysis directly in hot gel sample buffer.  Western blot analysis 
using anti-Pyk2 pY402 revealed that anti-ICAM1 beads, but not control beads, 
increased Pyk2 phosphorylation on Y402 (Figure 9A).  Thus, ICAM1 engagement 
activates not only Src, but also Pyk2.  To test whether the active form of this kinase 
is recruited to sites of ICAM1 engagement, we incubated TNF�-treated ECs with 
anti-ICAM1 beads, after which cells were fixed and stained using an antibody 
directed against Pyk2 pY402.  We found that the active form of Pyk2 was enriched 
at sites of ICAM1 engagement, but that control beads coated with mouse IgG did not 
recruit active Pyk2 (Figure 9B).  As before, ECs were incubated with anti-ICAM1 
beads and stained for Pyk2 pY402 or control proteins, �-catenin or VE-cadherin.  
ICAM1 engagement recruited active Pyk2, but not �-catenin or VE-cadherin (Figure 
9C).  The enrichment of active Pyk2 at sites of ICAM1 engagement further supports 
the role of ICAM1 in activating Pyk2. 
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Src and Pyk2 are required for ICAM1-mediated tyrosine phosphorylation of VE-
cadherin 
Our observation that ICAM1 engagement can recruit and activate both Src 
and Pyk2 led us to examine the roles of these kinases in ICAM1-mediated 
phosphorylation of VE-cadherin.  To test whether Src activity is required, we 
included PP2 or the inactive control compound, PP3, with anti-ICAM1 beads and 
incubated them with ECs as previously described.  Inclusion of PP2, but not PP3, 
with anti-ICAM1 beads completely inhibited ICAM1-mediated phosphorylation of VE-
cadherin on both Y658 and Y731 (Figure 10A).  Similar results were obtained using 
another Src inhibitor, SU6656 (data not shown).  Interestingly, inhibition of Src 
resulted in a reduction of VE-cadherin phosphorylation even below baseline levels.  
This suggests that Src family kinases are required not only for the ICAM1-mediated 
increase in VE-cadherin phosphorylation, but also for maintenance of low level 
phosphorylation which is perhaps part of normal VE-cadherin function.     
Because no pharmacological inhibitor of Pyk2 is available, we used an 
adenoviral delivery system to express CRNK (CAK�-related non-kinase) in ECs prior 
to treatment with anti-ICAM1 beads.  CRNK is an N-terminally truncated fragment of 
Pyk2 that acts in a dominant negative manner (96).  To rule out non-specific effects 
of adenoviral infection, control cells were infected with a GFP-expressing 
adenovirus.  ICAM1 engagement caused VE-cadherin phosphorylation in GFP-
expressing ECs.  By contrast, expression of CRNK decreased ICAM1-mediated VE-
cadherin phosphorylation at Y658 and Y731 (Figure 10B).  These results 
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demonstrate that both Src and Pyk2 are required for ICAM1-mediated 
phosphorylation of VE-cadherin. 
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Endothelial Src and Pyk2 activity is required for efficient neutrophil TEM 
Taking into account the role of Src in ICAM1-mediated phosphorylation of VE-
cadherin, we hypothesized that endothelial Src regulates cell-cell junctions during 
leukocyte TEM.  To test this hypothesis, we employed transwell transmigration 
assays using TNF�-treated ECs which were pretreated with vehicle control or the 
Src inhibitor PP2, and then washed thoroughly.  For these assays, primary human 
neutrophils were used.  In comparison to vehicle control, PP2 pretreatment 
dramatically decreased leukocyte transmigration  (71.1% +/- 3.8 reduction).  Similar 
results were obtained with another Src inhibitory compound, SU6656 (48.6% +/- 3.8 
reduction) (Figure 11A).  These results suggest that endothelial Src family kinase 
activity is required for leukocytes to pass between endothelial cells. 
We next tested whether Pyk2 activity is required for leukocyte TEM.  ECs 
were transduced with either GFP or CRNK and then used in transmigration assays.  
CRNK expression significantly attenuated neutrophil TEM compared to GFP controls 
(25.5%  +/- 6.0 reduction) (Figure 11B) indicating that endothelial Pyk2 also 
contributes to efficient neutrophil TEM.  
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VE-cadherin tyrosine phosphorylation on Y658 and Y731 is required for efficient 
neutrophil TEM  
To determine the importance of VE-cadherin phosphorylation on Y658 or 
Y731 in TEM, we generated adenoviruses expressing GFP-tagged mutants of VE-
cadherin in which tyrosines 658 or 731 were mutated to phenylalanine.  When 
expressed in ECs, mutant and wild type VE-cadherin localized to cell-cell junctions 
(Figure 12A).  ECs were infected with adenovirus expressing VE-cadherin-GFP 
Y658, VE-cadherin-GFP Y731, or wild type VE-cadherin-GFP such that expression 
was seen in 95-100% of cells.  Transmigration assays revealed that expression of 
either the Y658F or Y731F mutant caused a significant reduction in neutrophil 
transmigration (32.7% +/- 7.1, and 38.8% +/-6.5 reduction respectively) (Figure 
12B).  Taken together, these data suggest that ICAM1-mediated phosphorylation of 
VE-cadherin on tyrosines 658 and 731 plays an important role in neutrophil TEM, 
possibly mediating the opening of the cell-cell junctions during paracellular 
diapedesis.  
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Discussion  
In recent years, it has become clear that the process of leukocyte TEM 
involves a complex set of signals in both leukocytes and the endothelia.  Cues from 
adhesive interactions between the two cell types are responsible for coordination of 
these signals leading to efficient leukocyte TEM.  ICAM1 has emerged as a critical 
regulator of this process due to its role in leukocyte adhesion as well as its role in 
outside-in signaling pathways.  
Previous studies have shown that ICAM1 engagement has multiple effects on 
the actin cytoskeleton.  For example, ICAM1 crosslinking activates RhoA and 
induces stress fiber formation (97).  Resultant tension generated in the EC may 
stimulate the opening of cell-cell junctions (43-45).  ICAM1 interacts with several 
actin-binding proteins including -actinin 4, and ERM proteins (98, 99).  Work by 
Celli and colleagues demonstrates a functional requirement for the interaction 
between ICAM1 and -actinin 4 during leukocyte TEM (98).  Similarly, sequestration 
of endothelial ezrin or moesin away from sites of leukocyte adhesion blocks 
formation of endothelial docking structures as well as leukocyte TEM (99, 100).  
ICAM1 has also been shown to regulate the phosphorylation of the 
cytoskeletal regulatory protein, cortactin.  Yang and colleagues have demonstrated a 
requirement for Src-mediated phosphorylation of cortactin specifically in paracellular 
leukocyte TEM (59, 65).  It was also shown that cortactin phosphorylation is required 
for leukocyte-mediated cytoskeletal remodeling as well as clustering of ICAM1 (59).  
During, TEM, ICAM1 clustering is required for numerous signaling processes in ECs, 
thus Src-cortactin signaling may be the initiating event upstream of other ICAM1-
43
dependent signals (59).  In line with this, expression of VE-cadherin Y658F or Y731F 
mutants had no effect on the distribution or recruitment of ICAM1 to sites of 
leukocyte adhesion (data not shown) strengthening the idea that the ICAM-Src-
cortactin pathway functions upstream of VE-cadherin phosphorylation.  It is likely 
that Src activated downstream of ICAM1 engagement has numerous targets during 
leukocyte TEM.  The fact that Src has at least two targets which are localized to cell-
cell junctions, cortactin and now VE-cadherin, suggests that Src has important 
functions in paracellular leukocyte TEM.  In our system, we find that inhibition of 
endothelial Src strongly attenuates TEM of leukocytes.  This result is in accordance 
with Yang et. al., who have shown that inhibition of endothelial Src reduces TEM of 
neutrophils by roughly 40% (59, 65).  The multifaceted role of Src in paracellular 
TEM provides a likely explanation for why inhibition of Src blocks leukocyte TEM to a 
greater extent than Pyk2 inhibition, or specific blockade of VE-cadherin 
phosphorylation (Figures 9 and 10). 
While many studies of signaling by endothelial adhesion molecules, such as 
ICAM1 and VCAM1, have focused on regulation of the actin cytoskeleton or gene 
expression (10), the observation that VCAM1 crosslinking can cause formation of 
intercellular gaps suggests that signals generated by leukocyte adhesion also target 
cell-cell junctions (51).  Here we demonstrate that ICAM1-mediated signaling also 
regulates proteins of the adherens junctions during TEM.  Several lines of evidence 
lead us to propose a role for ICAM1-mediated phosphorylation of VE-cadherin in 
facilitating the paracellular passage of leukocytes.  We and others have observed 
that, in TNF-treated ECs, ICAM1 is enriched at endothelial cell-cell junctions (14, 
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94).  This localization places ICAM1 in an appropriate location from which to signal 
to the AJ.  Moreover, treatment of coronary artery endothelial cells with IL-1�
enhanced the proportion of monocytes using the paracellular route and this was due 
to IL-1�-mediated weakening of cell-cell junctions (13).  Thus, junctional integrity is 
important in regulating the transmigration of leukocytes by the paracellular pathway.  
Interestingly, ICAM1 signaling has previously been shown to be required for 
leukocyte-mediated disruption of cell-cell junctions in vitro. Specifically, adhesion of 
monocytes to TNF�-treated ECs causes displacement of VE-cadherin and 
associated catenins from the areas of cell-cell contact (15, 28).  This phenomenon 
was shown to be ICAM1 dependent, as pretreatment of leukocytes with blocking 
antibodies directed against the ICAM1 receptor, �2 integrin, inhibited leukocyte-
mediated disruption of junctions (28).  Another study demonstrated that antibody 
blockade of ICAM1-mediated adhesion causes monocytes to wander across the 
endothelium, failing to undergo diapedesis at cell-cell junctions (101).  Together, 
these data suggest that signals downstream from ICAM1 play an important role in 
junctional disassembly, which is required for paracellular leukocyte transmigration.  
ICAM1-mediated phosphorylation of VE-cadherin specifically on Y658 and 
Y731 may cause junctional disassembly by two potential mechanisms.  Previous 
work demonstrated that the phosphomimetic VE-cadherin mutant, Y731E, exhibits 
greatly decreased binding to -catenin (64).  Thus, phosphorylation on this residue 
would lead to uncoupling of VE-cadherin from the actin cytoskeleton, thereby 
weakening junctions and promoting leukocyte passage through the paracellular 
pathway.  Similar experiments with the Y658E VE-cadherin mutant suggested that 
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phosphorylation of Y658 reduces binding to p120-catenin (64).  Since it has been 
shown that interaction with p120-catenin stabilizes VE-cadherin at the junctions by 
preventing its clathrin-mediated endocytosis, the loss of p120-catenin binding may 
remove VE-cadherin from sites of paracellular TEM by an endocytic mechanism (19, 
20, 22).  Based on our data, we propose a model in which ICAM1 engagement near 
cell-cell junctions results in localized activation of Src and Pyk2 leading to 
phosphorylation of VE-cadherin on tyrosines 658 and 731. These signals then 
mediate junctional disruption at sites of leukocyte paracellular TEM, which allows 
leukocytes to pass across the endothelium (Figure 13).  In support of this model, we 
have shown that ICAM1 is capable of recruiting and activating both Src and Pyk2.  
Thus, leukocytes transmigrating at cell-cell borders will engage ICAM1 resulting in 
local activation of these kinases and accompanying phosphorylation of VE-cadherin. 
This work creates several intriguing directions for future studies.  For 
example, it is currently unclear which kinase directly phosphorylates VE-cadherin 
downstream of ICAM1 engagement.  The means by which Src and Pyk2 may 
regulate one another downstream from ICAM1 is also unknown.  Pyk2 and Src are 
known to interact and this interaction has been shown to contribute to the activation 
of both kinases (102-104).  However, differing reports regarding the 
interdependence of Src and Pyk2 in endothelial cells complicate speculation 
regarding the temporal regulation of these kinases in this pathway (102, 103, 105).  
Moreover, while we show that Src and Pyk2 are required for ICAM1-mediated VE-
cadherin phosphorylation, other intermediate signals, such as reactive oxygen 
species, may play a role in this pathway.   Finally, it is interesting to consider the role 
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of other adhesion molecules, such as VCAM1, in the regulation of endothelial AJs 
during leukocyte TEM.  Our preliminary studies suggest that VCAM-1 can also 
mediate phosphorylation of VE-cadherin and that VCAM1 can substitute for ICAM1 
in this pathway (Figure 6).  Of note, VCAM1 engagement has been shown to 
activate Rac1 resulting in generation of reactive oxygen species, which are capable 
of activating Pyk2 (51, 106).  Therefore, engagement of VCAM1 may further activate 
Pyk2 downstream of leukocyte adhesion to ECs.  The differences between the 
ICAM1- and VCAM1-mediated VE-cadherin phosphorylation pathways deserve 
further study.  It is interesting to note that Pyk2 phosphorylates -catenin, which also 
plays a role in regulation of EC junctional stability (53).  Thus, additional protein 
components of cell-cell junctions may be affected by signals triggered by leukocyte 
adhesion.  
Finally, VE-cadherin and its phosphorylation status may contribute to 
determining the route of leukocyte transmigration.  Our model predicts that 
expression of non-phosphorylatable VE-cadherin should reduce paracellular 
passage of leukocytes.  It is possible that blocking the paracellular pathway will be 
partially compensated by enhanced transcellular TEM.  In future work, we hope to 
explore this further. 
In conclusion, we have identified one step in the pathway by which leukocytes 
cause junctional disruption during paracellular TEM.  Enhanced leukocyte 
transendothelial migration and associated disruption of endothelial junctions has 
been implicated in pathologies ranging from multiple sclerosis to ischemia-
47
reperfusion injury.  Thus, the signaling processes elaborated in this work may serve 
as potential targets in the treatment of diverse inflammatory diseases. 
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Materials and Methods 
 
Reagents and Abs – Phosphospecific polyclonal antibodies against Src 
pY418, Pyk2 pY402, VE-cadherin pY658 and VE-cadherin pY731 were obtained 
from Biosource International (Camarillo, CA).  Monoclonal PY-20 anti-
phosphotyrosine antibodies were obtained from BD Transduction Laboratories 
(Lexington, Kentucky).  Monoclonal antibodies against VE-cadherin were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant TNF, anti-ICAM1, 
anti-VCAM1, and IgG monoclonal antibodies were from R&D Systems (Minneapolis, 
MN). Src-kinase inhibitors PP2, SU6656 as well as the control compound PP3, were 
purchased from Calbiochem (Darmstadt, Germany). The wild type VE-cadherin-GFP 
adenovirus was a kind gift of Drs. F. Nwariaku and D. Nahari (University of Texas 
Southwestern, Dallas, TX).  CRNK adenovirus was a kind gift of Dr. L. Graves 
(University of North Carolina, Chapel Hill, NC).  All other adenoviral constructs were 
generated using the Virapower Adenoviral Expression System (Invitrogen) according 
to manufacturer’s instructions. 
Cell cultures, treatments and transfections - HUVECs were obtained from 
Cambrex (East Rutherford, NJ) and cultured as described previously (89). To mimic 
inflammation and to enhance ICAM1 expression, endothelial cells were activated 
with 10ng/ml TNF- overnight as indicated. To block ICAM1 function, anti-ICAM1 
antibodies were used at 10 µg/ml for one hour.  All cell lines were cultured or 
incubated at 37°C at 10% CO2. THP-1 cells were obtained from the UNC 
Lineberger Comprehensive Cancer Center Tissue Culture Facility and grown in 
RPMI plus 10% fetal bovine serum plus 0.05 mM 2-mercaptoethanol. HL-60 cells 
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were obtained from UNC-LCCC Tissue Culture Facility and grown in Optimem plus 
10% fetal bovine serum. Differentiation to a granulocytic lineage was achieved by 
adding 1.3% DMSO for 3–5 days (107).  Primary human neutrophils were isolated 
from healthy volunteers according to IRB-approved protocols as described 
previously (108).  Briefly, 50 mL blood was added to 10 mL of 10% trisodium 
citrate/phosphate-buffered saline.  Monocytes and platelets were removed using 
density gradient centrifugation over isotonic Percoll (Pharmacia, Uppsala, Sweden).  
Erythrocytes were lysed by resuspending the pellet fraction in ice-cold isotonic 
NH4Cl solution (155 mM NH4Cl, 10 mM KHC03, 0.1 mM EDTA, pH 7.4).  Remaining 
neutrophils were washed once in PBS and resuspended in DMEM plus 0.25% BSA 
for transmigration experiments. 
Immunoprecipitations of tyrosine phosphorylated VE-cadherin.  ECs were 
treated as described, lysed directly in hot gel sample buffer (200 mM Tris pH 6.8, 
20% glycerol, 4% SDS, 5% 2-mercapto ethanol), and boiled for 10 minutes.  
Samples were then diluted with 20 volumes of 1% Triton X100, 1% DOC in TBS.  2 
µg of PY20 monoclonal anti-phosphotyrosine antibody and protein G sepharose 
were added and samples were incubated 4 hours at 4 degrees.  Samples were then 
washed 5 times in 1% Triton X100, 1% DOC in TBS and analyzed by western blot 
using anti-VE-cadherin antibody. 
Western blotting - For biochemistry, 10 ug/mL of antibody-coated beads were 
incubated on cells which were then washed twice gently with ice-cold Ca2+- and 
Mg2+-containing PBS and lysed in 35 µL of boiling sample buffer.  Cells were 
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scraped from the dishes and samples were boiled immediately for 10 minutes.  
Samples were then analyzed by Western blotting using an enhanced 
chemiluminescence (ECL) detection system from Amersham (Piscataway, NJ).  The 
intensity of bands was quantified using the NIH Image-J 1.36, developed at the 
National Institutes of Health and freely available at http://rsb.info.nih.gov/nih-image/. 
Results were then subjected to statistical analysis using Student’s t-test.  P-values 
less than 0.05 were considered significant. 
Immunocytochemistry (IF) – Cells were cultured on glass cover slips, fixed 
and immunostained with the indicated primary antibodies using the protocol 
previously described (89). Subsequent visualization was performed with ALEXA-
conjugated secondary Abs obtained from Molecular Probes/Invitrogen (Carlsbad, 
CA). Images were recorded with a ZEISS LSM510 confocal microscope with 
appropriate filter settings. Bleed through between channels was avoided by use of 
sequential scanning.  
Antibody coated beads – Three micron polystyrene beads were purchased 
from Polysciences Inc. (Warrington, PA) and were pretreated overnight with 8% 
glutaraldehyde, washed 5x with PBS and incubated with 300 µg/mL ICAM1 or 
VCAM1 mAb according to the manufacturers protocol. 
Leukocyte and bead adhesion assays - For immunofluorescence, a 1:100 
dilution of bead slurry was incubated in 24-wells containing glass cover slips, on 
which TNF�-pretreated HUVECs were cultured.  After 10 minutes, unbound beads 
were washed away and coverslips were subsequently processed for IF.  For 
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biochemistry, 900 µL of a 1 to 30 dilution of bead slurry was incubated on HUVECs 
cultured in 6-well dishes.  For leukocyte adhesion assays, 1x106 THP-1 or HL-60 
cells were used per well of a 6-well dish.  THP-1 cells were washed 3 times in 
HUVEC growth media and incubated with ECs for various times before lysis in hot 
sample buffer and subsequent processing. 
 
Transendothelial migration assay - Migration assays were performed using 
Transwell filters of 6.5 mm diameter with 8 µm pores as described previously (26).  
Briefly, ECs were grown to confluence on matrigel-coated Transwell filters and 
treated with TNF� overnight.  The lower chamber was filled with assay media 
(DMEM plus 0.25% BSA) plus 5 ng/mL IL-8 as chemoattractant.  ECs were washed 
twice with assay media and subsequently incubated with 1x105 neutrophils at 37°C, 
10% CO2, for 1 hour. Transmigration was quantified by counting transmigrated cells 
in the lower chamber using a hemocytometer.  To check efficient expression of 
transduced constructs, cells were simultaneously grown in 24-well dishes and 
treated with an equivalent amount of adenovirus and analyzed by IF.  
 
Chapter 3: ICAM1-dependent RhoG activation is required for leukocyte 
transendothelial migration. 
 
Summary 
During transendothelial migration, leukocyte integrins bind endothelial surface 
proteins such as ICAM1 to adhere to the endothelium. Subsequently, the 
endothelium forms docking structures, dynamic membrane protrusions that partially 
surround adherent leukocytes. However, little is known about the signaling pathways 
that regulate these structures. Here we show that RhoG is activated downstream 
from ICAM1 engagement and that this requires the intracellular domain of ICAM1.  
ICAM1 co-localizes with RhoG and binds to the RhoG-specific guanine-nucleotide 
exchange factor SGEF.  In addition, the SH3 domain of SGEF mediates its 
interaction with the cytoplasmic tail of ICAM1.  Depletion of endothelial RhoG by 
siRNA did not affect leukocyte adhesion but decreased the formation of docking 
structures and inhibited leukocyte transendothelial migration.  Similarly, silencing 
SGEF resulted in a significant reduction in cup formation and TEM.  Together these 
results identify a new signaling pathway involving RhoG and its exchange factor 
SGEF downstream from ICAM1 that is critical for leukocyte TEM. 
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Introduction   
Leukocyte transendothelial migration (TEM) is a key event in host defense. 
The passage of leukocytes across the vascular wall into the underlying tissues can 
be divided into distinct phases including firm adhesion of leukocytes to the 
endothelium and subsequent diapedesis (5). Leukocyte adhesion to the endothelium 
initiates the formation of so-called docking structures; these are dynamic dorsal 
membrane protrusions that resemble a cup-like structure (12, 49, 54). These 
structures surround adherent leukocytes, contain the cell adhesion molecules 
ICAM1 and VCAM1, and are essential for proper transmigration. However, little is 
known about the mechanisms that regulate the formation of these docking 
structures.   
During TEM, leukocytes bind and cluster ICAM1 on the endothelial cell 
surface, which triggers diverse signals within endothelial cells (10). Leukocyte 
engagement of ICAM1 can be mimicked by crosslinking ICAM1 with ICAM1-specific 
antibodies (46, 66, 97) or by ICAM1-antibody coated beads (59, 109). It has been 
shown that crosslinking of ICAM1 results in the rearrangement of the actin 
cytoskeleton and increased actin stress fibers (26, 97).  Moreover, preventing actin 
polymerization with cytochalasin D dramatically reduced leukocyte TEM (12, 110). In 
addition, Carman and Springer showed recently that actin polymerization is required 
for the formation of docking structures (12). These findings indicate the importance 
of endothelial actin dynamics in leukocyte TEM.  
Actin membrane dynamics are controlled by small Rho-like GTPases. These 
proteins function as molecular switches and cycle between an inactive GDP-bound 
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state and an active GTP-bound state.  Blocking RhoA activity using C3-endotoxin 
prevents migration of leukocytes across endothelial cell monolayers (97, 110).  
However, the role of RhoA in the formation of docking structures remains somewhat 
controverisial since one group found that C3 was unable to prevent cup formation 
while another demonstrated that inhibition of Rho-kinase using Y27632 blocked 
formation of docking structures  (12).  It has been observed that the docking 
structures formed around a leukocyte resemble a phagocytic cup (49, 54).  Recently, 
the Rac1-related GTPase RhoG was implicated in phagocytosis of apoptotic cells 
(111).  These findings led us to examine RhoG as a candidate in regulating 
leukocyte TEM through the formation of docking structures. 
Here we demonstrate that SGEF and RhoG are critical mediators of leukocyte 
TEM. RhoG and SGEF, a guanine-nucleotide exchange factor for RhoG, are 
recruited to sites of ICAM1 engagement. We demonstrate that crossliking ICAM1 
leads to activation of RhoG.  Additionally, we find that ICAM1 interacts directly with 
the SH3 domain of SGEF.  Finally, siRNA targetting of RhoG or SGEF inhibits 
formation of docking structures and migration of leukocytes across endothelial cell 
monolayers.   
Much of the work presented in this chapter was produced in close 
collaboration with Jaap van Buul.  Experimental strategies were generated together 
and I generated many of the ICAM1 and RhoG constructs required to investigate 
how ICAM1 activates RhoG.  In addition, some preliminary imaging studies, 
especially the SEM studies (Figure 14D) were done together with Jaap van Buul.  In 
this chapter, my own work was primarily focused on testing my hypothesis that a 
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putative proline-rich domain in the ICAM1 intracellular tail binds to the SH3 domain 
of SGEF and that this interaction likely plays a role in leukocyte TEM.  This 
hypothesis was generated as a result of work performed primarily by Jaap van Buul 
in which he demonstrated that ICAM, SGEF, and RhoG colocalize in cells, and that 
ICAM1 crosslinking activates RhoG (Figures 15-18).  Jaap van Buul was also 
responsible for the siRNA studies examining the requirement for RhoG and SGEF in 
formation of docking structures and leukocyte TEM.  These data have been included 
in this thesis in order to provide context and physiological relevance for my own work 
with ICAM1 and SGEF.  
 
Results 
Endothelial cells form docking structures around leukocytes.  
Adhesion of myeloid leukemia HL-60 cells to TNF�-treated endothelial cells resulted 
in recruitment of ICAM1 to sites of adhesion (Figure 14A), as well as ICAM1-positive 
membrane protrusions that surrounded the adhered leukocyte (Figure 14B). Also, 
GFP-actin, transiently expressed in endothelial cells, distributed to sites of leukocyte 
binding and co-localized with ICAM1 (Figure 14C). Of note, the endothelial cell-cell 
junctional marker VE-cadherin did not localize to these membrane protrusions 
(Figure 14A).  Three dimensional projections showed that ICAM1-positive 
protrusions arose from the apical plane of the endothelial cells, but did not fully cover 
the leukocyte (Figure 14B). These protrusions resembled cup-like structures that 
extended approximately 6-7µm above the baso-lateral membrane (Figure 14B-d). 
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Scanning electron microscopy (SEM) confirmed the presence of endothelial 
membrane protrusions surrounding but not fully covering adhered leukocytes at this 
time point (Figure 14D).  
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RhoG and SGEF colocalize with ICAM1.  
Docking structures are strikingly similar to phagocytic cups seen in other cell 
systems.  Recently, the small GTPase RhoG has been implicated in the phagocytic 
pathway (111).  In addition, the small GTPase RhoG and its specific guanine-
nucleotide exchange factor SGEF are known to induce dorsal membrane ruffles, 
which also resemble both phagocytic and docking structures (112).  These 
observations, coupled with the role of ICAM1 in mediating formation of docking 
structures led us to examine the possibility that SGEF and/or RhoG might be 
recruited to sites of ICAM1 engagement.  We first examined whether all these 
proteins were  
expressed in endothelial cells and found that RhoG and SGEF are endogenously 
expressed in endothelial cells, as well as in Cos7 and Hela cells (Figure 15A). 
To study potential localization of ICAM1 to dorsal ruffles, Cos7 cells that lack 
endogenous ICAM1 were used.  Expression of ICAM1, tagged with GFP or the V5 
epitope showed distributions similar to endogenous ICAM1 in endothelial cells.  
Interestingly, co-transfection of RhoG-Q61L or SGEF not only induced dorsal ruffles 
but also induced a redistribution of ICAM1 to these ruffles (Figure 15B). ICAM1 co-
localized with RhoG-Q61L or SGEF (Figure 15B). The localization of ICAM1 to 
ruffles required active RhoG or SGEF, since neither RhoG-wt nor a dominant 
negative mutant, T17N, co-localized with ICAM1 (data not shown).  As a control, the 
transmembrane protein PECAM-1 was expressed together with RhoG-Q61L or 
SGEF and showed no co-localization (data not shown).   
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RhoG and SGEF are recruited to sites of ICAM1 engagement.
The finding that ICAM1, SGEF and active RhoG colocalize in cells, coupled 
with the role of ICAM1 in mediating formation of docking structures, led us to 
examine whether SGEF or RhoG are recruited to sites of ICAM1 engagement.  To 
specifically study ICAM1 engagement and downstream signaling that would mimic 
leukocyte binding to ICAM1, anti-ICAM1 beads were used.  These beads specifically 
adhered to ICAM1 and recruited ICAM1-V5 within 30 minutes (Figure 16A).  The 
anti-ICAM1 beads did not bind to VCAM1-GFP-transfected cells or to non-
transfected cells (data not shown).  In addition, blocking Abs to ICAM1 completely 
inhibited binding of the �ICAM1-beads to ICAM1 (data not shown).  To show that 
ICAM1 was recruited specifically to the beads, co-transfections with ICAM1-V5 and 
GFP, as a control, were carried out and showed that GFP alone was not recruited to 
sites of adhesion (Figure 16A).  We observed that both GFP-SGEF and GFP-RhoG-
Q61L were recruited to sites of ICAM1 engagement (Figure 16A).  In contrast, 
neither -catenin-GFP nor VE-cadherin-GFP was recruited to sites of ICAM1 
engagement (data not shown).  Quantification of ICAM1, SGEF, RhoG-Q61L, GFP, 
-catenin and VE-cadherin recruitement by anti-ICAM1 beads is shown in figure 
16B.  
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RhoG is activated upon ICAM1 engagement and requires the intracellular tail of 
ICAM1 and Src-kinase activity.   
Because RhoG and SGEF colocalize to sites of ICAM1 engagement, we next 
performed RhoG activation assays to determine whether engagement of ICAM1 
could trigger activation of RhoG.  We made use of the RhoG downstream effector 
ELMO, which specifically binds GTP-bound RhoG (112, 113).  In our initial 
experiments, we used an adenoviral system to deliver myc-tagged RhoG to 
HUVECs and found that clustering of ICAM1 with anti-ICAM1 beads induced RhoG 
activation (Figure 17A).  Examining endogenous RhoG using a monoclonal antibody 
revealed a similar activation in response to ICAM1 (Figure 17B).  To study the 
pathway downstream from ICAM1, Myc-tagged RhoG-wt and ICAM1-GFP were 
expressed in Cos7 cells.  Treatment with anti-ICAM1 beads induced a robust RhoG 
activation (Figure 17C).  Beads coated with IgG did not induce any RhoG activation 
(data not shown).  To examine whether leukocytes could activate RhoG through 
ICAM1, we plated differentiated HL-60 cells on the ICAM1-expressing Cos7 cells 
and found that RhoG activation was stimulated by adhesion of HL-60 cells (Figure 
17D).   
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Previously, it has been shown that the intracellular tail of ICAM1 is required for 
leukocyte passage across the endothelium but is dispensable for the initial adhesion 
(114). To investigate whether the intracellular tail of ICAM1 is required to transmit 
the signal that triggers RhoG activation, a C-terminal deletion mutant of ICAM1, 
lacking the intracellular tail (ICAM1-�C), was generated and expressed in Cos7 
cells. No difference in adhesion of anti-ICAM1 beads to either the full-length or 
ICAM1-�C was observed (data not shown).  However, the anti-ICAM1 beads were 
unable to activate RhoG in cells expressing ICAM1-�C and Myc-RhoG-wt (Figure 
18A).   
 Several studies including those presented in this thesis have shown that 
ICAM1 engagement activates Src-kinase (46, 58, 109).  Therefore, we tested 
whether Src-kinase activity was required for ICAM1-mediated RhoG activation.  
Treatment of cells with PP2, a Src-kinase inhibitor, blocked ICAM1-mediated RhoG 
activation (Figure 18B).  Together, these data show that ICAM1 engagement 
induces Src-kinase-dependent RhoG activation through its intracellular tail. 
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ICAM1 associates with SGEF through its SH3 domain.  
 The finding that RhoG is activated downstream from ICAM1 engagement, 
and that this process requires the ICAM1 intracellular tail, coupled with the 
observation that SGEF colocalizes with ICAM1, led us to investigate whether ICAM1 
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and SGEF physically interact.  Immunoprecipitation studies showed that 
endogenous ICAM1 was precipitated with endogenous SGEF from TNF-�-treated 
endothelial cells (Figure 19A).  To study this interaction in more detail, pull-down 
experiments were performed using biotinylated peptides that correspond to the 
intracellular tail of ICAM1.  A peptide corresponding to the cytoplasmic domain of 
ICAM1 bound Myc-tagged SGEF (data not shown) as well as endogenous SGEF 
(Figure 19B).   
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Interestingly, although the intracellular tail of ICAM1 comprises only 28 amino-acids, 
the 9 most C-terminal residues include four prolines.  This led us to hypothesize that 
the SH3 domain of SGEF may play a role in mediating ICAM1 binding.  To explore 
this posibility, we expressed ICAM-GFP with either an SGEF mutant lacking the SH3 
domain (SGEF-�SH3) or an SGEF mutant lacking the DH domain (SGEF-�DH).  We 
found that SGEF-�SH3 failed to bind ICAM1-GFP (Figure 20A).  However, SGEF-
�DH, which contains the SH3 domain, bound ICAM-GFP suggesting that the 
exchange activity of SGEF is not required for its binding to ICAM1.  To futher confirm 
the role of the SGEF SH3 domain in mediating binding to ICAM1, we employed an 
inactivating point mutant in the SH3 domain of SGEF (Myc-SGEF-W826R) which 
was previously generated in our lab (112).  This construct or wild-type SGEF were 
overexpressed in Cos7 cells, together with ICAM1-GFP and immunoprecipitation 
assays confirmed that SGEF-wt interacted with ICAM1 while SGEF-W826R showed 
greatly decreased binding (Figure 20B).  To test the role of the ICAM1 proline-rich 
domain in SGEF binding, we additionally generated a GFP-tagged deletion mutant 
of ICAM1 lacking the proline-rich domain and used this in coimmunoprecipitation 
experiments with wild-type myc-tagged SGEF.  Compared to wild-type ICAM1, the 
proline deletion mutant failed to interact with SGEF (Figure 20C).  In order to 
determine whether the SH3 domain of SGEF could directly associate with  
the cytoplasmic domain of ICAM1, we incubated biotinylated ICAM1-intracellular tail 
peptide with a bacterially expressed and purified GST fussion of the SH3 domain of 
SGEF (GST-SH3-SGEF).  We found that GST-SH3-SGEF bound to the ICAM1-
intracellular tail peptide, but not to a control peptide (Figure 20D).  These data 
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demonstrate that SGEF directly interacts with the cytoplasmic tail of ICAM1 and that 
this interaction requires both the SGEF SH3 domain and the proline-rich region of 
ICAM1.  
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SGEF and RhoG are required for docking structure formation and leukocyte 
transendothelial migration.  
To study RhoG involvement in transendothelial migration, siRNA was used to 
knock down RhoG expression in primary endothelial cells.  Western blot analysis 
revealed that the relevant siRNA knocked down RhoG protein expression in 
endothelial cells, but not other small GTPases or other proteins known to be present 
in docking structures, such as moesin and ICAM1 (49, 54, 100) (Figure 21A). 
Adhesion of leukocytes to RhoG-deficient endothelial monolayers was not affected 
(data not shown).  However, the formation of docking structures, quantified as 
ICAM1-positive ring-like structures that surrounded adhered leukocytes was 
decreased compared to control cells (Figure 21B).  Quantification of the docking 
structures showed that silencing RhoG resulted in a significant decrease in cup 
formation (Figure 21B). Migration of differentiated HL-60 cells across RhoG-deficient 
endothelial cells was also significantly attenuated (Figure 21C). Interestingly, RhoG 
inhibition not only inhibited chemokine-induced transendothelial migration, but also 
decreased basal transendothelial migration.  
Reduction of SGEF expression using siRNA effectively reduced SGEF protein 
levels without affecting RhoG levels or other proteins known to be involved in the 
formation of docking structures (Figure 22A).  Reducing SGEF expression lowered 
the number of ICAM1-positive rings surrounding adherent leukocytes (Figure 22B). 
In addition, SGEF siRNA treatment caused a significant decrease in migration of HL-
60 cells across endothelial monolayers (Figure 22C). These data indicate that both 
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RhoG and SGEF are required for optimal transmigration of leukocytes across 
endothelial monolayers. 
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Discussion 
During the last decade, it has become increasingly clear that endothelial cells 
actively participate in the process of leukocyte transendothelial migration (TEM).  
This chapter focuses on a recently discovered phenomenon that occurs during TEM 
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in which the endothelial cell actively protrudes sheets of membrane around adherent 
leukocytes forming so-called docking structures (12, 49, 54, 100).  Importantly, these 
structures appear to be required for optimal leukocyte TEM (12).  In this work, we 
have characterized a new signaling pathway wherein RhoG activation is triggered by 
the engagement of ICAM1.  This signaling pathway is critical for the formation of 
docking structures, and for optimal leukocyte passage across the endothelium.   
ICAM1 is a transmembrane glycoprotein that localizes at the apical side of the 
endothelium and is involved in the adhesion of leukocytes to this surface (10).  
Inflammatory stimuli, such as TNF� and IL-1�, increase the expression of ICAM1 on 
the endothelium 5 to 10 fold, which results in increased leukocyte extravasation 
(115). The ICAM1-receptor on leukocytes, integrin �L�2 (LFA1), binds and clusters 
ICAM1, triggering intracellular signals within the endothelium that in turn facilitate 
leukocyte TEM (10).  However, the details of this process are not well understood.  
Millán and co-workers have shown that the redistribution of ICAM1 to caveolin-rich 
membrane domains in response to engagement is followed by transcytosis to the 
baso-lateral side of the endothelium (94).  
Inhibitor studies suggested that the small GTPases Rac or Cdc42 are likely to 
be involved in the formation of the docking structures (12).  RhoG, a close relative of 
Rac1 (12), induces dorsal membrane ruffles and is activated downstream of ICAM1 
engagement. The intracellular tail of ICAM1 is a prerequisite for optimal 
transendothelial migration of leukocytes (114).  ICAM1, lacking its intracellular tail 
(ICAM1-�C), fails to promote leukocyte TEM, although leukocyte adhesion to 
ICAM1-�C is unaffected.  The finding that engagement of ICAM1-�C by anti-ICAM1 
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beads is unable to activate RhoG suggests that RhoG is required for the initial 
binding of leukocytes to the endothelium.  The fact that ICAM1-�C cannot activate 
RhoG is likely due to its inability to bind SGEF.   In support of this, we find that the 
intracellular tail of ICAM1 directly binds the SH3 domain of SGEF.  This interaction is 
independent of SGEF activation, because catalytically inactive mutants of SGEF that 
express the SH3 domain still bind ICAM1.  Importantly, we find that the proline-rich 
region of ICAM1 is required for binding to SGEF.  This represents the first evidence 
that the cytoplasmic tail of ICAM1 contains a functional proline-rich domain, which 
could mediate binding to other SH3-domain-containing proteins.   Engagement of 
ICAM1 does not promote the association between SGEF and ICAM1 (personal 
observation, JDvB), but does increase the activation of SGEF, as judged by the 
increased binding of SGEF with nucleotide-free RhoG (personal observation JDvB).  
Thus, SGEF and ICAM1 likely form a stable interacting pair.  Other signals, such as 
tyrosine phosphorylation, may be necessary to trigger SGEF activation, as has been 
shown for other GEFs (116).  One such signal may depend on Src-kinase activity.  
In this thesis we show that Src-kinase is rapidly activated after ICAM1 engagement 
and required for optimal leukocyte TEM (Figures 6, 9A) (46, 58, 65, 109).  In 
accordance with these findings, we show that Src-kinase activity is required for 
RhoG activation downstream from ICAM1 engagement. These data support the 
hypothesis that additional signals are needed to activate SGEF downstream of 
ICAM1 engagement. 
Our data results suggest a role for SGEF in the formation of docking 
structures by triggering RhoG activation downstream from ICAM1. Silencing SGEF 
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by siRNA inhibits leukocyte TEM to the same degree as siRNA targeted against 
RhoG suggesting that these molecules function in a single pathway.  In the future it 
will be important to further examine precisely whether and how ICAM1 activates 
SGEF and the role of SGEF in ICAM1-mediated RhoG activation  
 In this chapter, we have identified SGEF as a novel ICAM1 binding partner 
whose expression is required for efficient leukocyte TEM.  Additionally, our data 
suggest that RhoG functions downstream of ICAM1 clustering to facilitate the 
formation of docking structures.  Thus, the ICAM1-RhoG pathway may be a central 
regulator of leukocyte extravasation, an event that is critical in inflammation and 
immune surveillance. 
 
Materials and Methods  
Reagents and Abs - Monoclonal antibodies (mAbs) against Rac1, VE-
cadherin and -catenin were purchased from BD Transduction Laboratories 
(Lexington, KY). Polyclonal Abs against RhoG (A20,C20,D18), ICAM1 (for WB) and 
-catenin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
Recombinant Tumor-Necrosis-Factor (TNF)- and a mAb against ICAM1 were from 
R&D Systems (Minneapolis, MN); A mouse polyclonal Ab against RhoG was 
obtained from Abnova (Taiwan). The GFP, V5 and Myc mAb (clone 9E10) were 
purchased from Invitrogen (Carlsbad, CA). Src-kinase inhibitor PP2 was purchased 
from Calbiochem (Darmstadt, Germany). The SGEF rabbit polyclonal Ab was 
generated in our laboratory as described (112). The monoclonal antibody against 
RhoG was raised in the laboratory of Dr. Schwartz against C-terminal RhoG peptide 
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(AA162-180) of the following sequence: QQDGVKEVFAEAVRAVLNPT. Dot-blots 
showed that the mAb did not cross-react with bacterially expressed Rac1, Cdc42 
and RhoA. 
Expression Vectors - SGEF cDNA was subcloned using BamHI/EcoRI 
restriction sites into pCMV6M, an amino-terminal Myc epitope-tagged eukaryotic 
expression vector as described (112). SGEF deletion mutants were generated using 
Quikchange site-directed mutagenesis kit and subcloned into pCMV6M. pGEX-4T2-
ELMO was a kind gift of Dr. Kodimangalam Ravichandran, University of Virginia. 
Generation of eukaryotic expression vectors pCMV-Myc-Rac(Q61L), pCMV-Myc-
Rac-wt, pCMV-Myc-Rac(T17N), pCMV-Myc-RhoG(Q61L), pCMV-Myc-RhoG-wt and 
pCMV-Myc-RhoG(T17N) was described previously by our laboratory (117). Wild-type 
and mutant Rac1 and RhoG constructs were subsequently subcloned into the 
pEGFP-C3 (Clontech, Mountain View, CA) as described (117). SGEF was 
subcloned into the pEGFP-C2. ICAM1-GFP was a kind gift from Dr. Sanchez-Madrid 
(Madrid, Spain). ICAM1-wt and C-terminal deletion mutant cDNA was subcloned into 
the pAdCMV-V5-DEST vector using the Gateway expression system (Invitrogen).  
Cell cultures, treatments and transfections - HUVECs were obtained from 
Cambrex (East Rutherford, NJ) and cultured as described previously (118). 
Endothelial cells were activated with 10ng/ml TNF- overnight as indicated, to mimic 
inflammation. All cell lines were cultured or incubated at 37°C at 10% CO2. The HL-
60 pro-myelocytic cell line was obtained from UNC-LCCC Tissue Culture Facility and 
grown in Optimem plus 5% fetal bovine serum. Differentiation to a neutrophil-like 
lineage was achieved by adding 1.3% DMSO for 3–5 days (107). Cos7 cells were 
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maintained in growth medium (DMEM with 10% fetal calf serum; Sigma). Cells were 
transiently transfected with the expression vectors indicated in each experiment 
according to the manufacturer's protocol using LipofectAMINE PLUS (Invitrogen) or 
Fugene6 (Roche, Basel, Swiss).  Myc-tagged RhoG adenovirus was generated 
using the Invitrogen Gateway system according to manufacturer’s instructions. 
Immunofluorescence (IF) – Cells were cultured on glass cover slips, fixed and 
immunostained with indicated primary Abs as described previously (26). Subsequent 
visualization was performed with Alexa-conjugated secondary Abs (Invitrogen). F-
actin was visualized with fluorescently-labeled Phalloidin (Invitrogen). Images were 
recorded with a ZEISS LSM510 confocal microscope with appropriate filter settings. 
Bleed through between different channels was avoided by use of sequential 
scanning.  
Scanning Electron Microscopy (SEM) - Cells were grown on glass cover slips 
and then fixed in 2.5% glutaraldehyde/PBS for 30 min at room temperature and 
processed for SEM as described (112). Briefly, samples were incubated with 2% 
aqueous osmium tetroxide for 45 min, dehydrated in a graded ethanol series, and 
then critical point dried in liquid CO2 using the Balzers CPD 010 (Balzers 
Instruments, Balzers, Liechtenstein). Samples were mounted on aluminum stubs 
(Ted Pella Inc., Redding, CA) and sputter-coated with gold/palladium using the 
Polaron SEM. Cells were examined on a JEOL 820 scanning electron microscope 
(Peabody, MA) at 15 kV. 
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Transendothelial migration assay - Migration assays were performed in 
Transwell plates (Corning, Corning, NY) of 6.5-mm diameter with 8-µm pore filters as 
described (26). Briefly, endothelial cells were grown to confluence on matrigel-
coated Transwell-filters and treated with TNF-� O/N. Transwell plates were 
incubated at 37°C, 10% CO2, for 4h. SDF-1 (R&D systems) was placed in the lower 
chamber to generate a chemotactic gradient. To confirm efficient knock down of the 
protein by siRNA, cells were simultaneously grown in 6-well plates and equally 
treated with siRNA constructs and analyzed by Western blot. 
Immunoprecipitation (IP) and Western blotting - Cells were grown to 
confluency, washed twice gently with ice-cold Ca2+- and Mg2+-containing PBS and 
lysed in 300µL of lysis buffer (25mM Tris, 150mM NaCl, 10mM MgCl2, 1% Triton X-
100, with the addition of fresh protease-inhibitors; pH 7.4). IP was performed as 
previously described and analyzed by Western blotting using an enhanced ECL 
detection system (GE Healthcare, Piscataway, NJ) (112). The intensity of the bands 
was quantified by using the NIH Image-J 1.36, developed at the National Institutes of 
Health and freely available at http://rsb.info.nih.gov/nih-image/. 
Docking structure quantification – Using confocal laser scanning microscopy, 
Z-stacks were taken to confirm the formation of a docking structure around an 
adhered leukocyte. The length of the protrusion was approximately 6µm above the 
baso-lateral plane of the substrate. The apical plane was set to 4µm from the baso-
lateral plane. ICAM1-positive rings in the apical plane were counted as positive 
docking structures. 
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RhoG Activation Assay - For RhoG activation assays, an adenoviral system 
was used for transient expression of Myc-tagged RhoG due to the lack of a high 
affinity Ab that is appropriate for these assays, as described by Katoh and Negishi 
(113). Transfected cells were lysed in 300µL of 50mM Tris, pH 7.4, 10mM MgCl2,
150mM NaCl, 1% Triton X-100, 1mM PMSF and 10 µg/mL each of aprotinin and 
leupeptin. Lysates were cleared at 14,000g for 10 min. Supernatants were rotated for 
30 min with 60-90µg of GST-ELMO (GST fusion protein containing the full-length 
RhoG effector ELMO) conjugated to glutathione-Sepharose beads (GE Healthcare). 
Beads were washed in 50mM Tris, pH 7.4, 10mM MgCl2, 150mM NaCl, 1% Triton X-
100, and protease inhibitors. Pulldowns and lysates were then immunoblotted for the 
c-Myc epitope tag. 
Fusion Proteins - GST-ELMO, GST-SGEF-SH3 (SGEF789-850) and GST-
RhoG-15A fusion proteins were purified from BL21 E.coli cells (Stratagene, La Jolla, 
CA) using glutathione-Sepharose 4B as previously described (112). GST fusion 
proteins were eluted with free, reduced glutathione in TBSM (50mM Tris, 150mM 
NaCl, 5mM MgCl2, 1mM DTT) and stored in 30% glycerol at -80ºC.  
Anti-ICAM1-antibody coated beads - Polystyrene beads (3µm; Polysciences 
Inc., Warrington, PA) were pretreated with 8% glutaraldehyde O/N, washed 5 times 
with PBS and incubated with 300µg/mL ICAM1 mAb according to the manufacture’s 
protocol. 
Bead adhesion assay - For IF or SEM, 1µg/mL of Ab-containing-beads were 
washed and re-suspended in assay medium (DMEM, supplemented with 10% fetal 
bovine serum). 1µg/mL of Ab-coated beads was incubated in wells of 24-well dishes 
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containing glass cover slips, on which TNF-�-pretreated HUVECs or Cos7 cells were 
cultured. After the appropriate time, unbound beads were removed and cover slips 
were put on ice, gently washed 3 times with ice-cold PBS containing 1mM Ca2+/Mg2+ 
and subsequently processed for IF. For biochemistry, 10µg/mL of Ab-coated beads 
were incubated on the cells after which cells were washed as described above and 
subsequently lysed and processed as described. 
Knock down using siRNA - siRNA duplexes against human RhoG and SGEF 
mRNA were obtained from the Dharmacon Inc. (Chicago, IL) siRNA collection. 
siRNA duplexes against human caveolin-1 and -2 mRNA were obtained from the 
Santa Cruz siRNA collection. HUVECs were transfected twice with 50nmol/L of 
siRNA using RNAfect transfection reagent (Qiagen, Chatsworth, CA). After 48 hours, 
cells were processed as described. 
 
Chapter 4: Conclusions and Future Prospects. 
In this thesis, work has been presented which details two novel functions for 
ICAM1 in transendothelial migration of leukocytes.  ICAM1 was shown to mediate 
tyrosine phosphorylation of VE-cadherin, which was required for neutrophil TEM.  In 
addition, an interaction between ICAM1 and the RhoG-specific GEF SGEF was 
demonstrated.  This interaction is proposed to play a role in ICAM1-mediated RhoG 
activation which is also required for leukocyte TEM.  The work presented has 
generated many new questions regarding both the mechanisms of ICAM1 signaling 
as well as the functions of these signals in regulating leukocyte transmigration.  In 
the following chapter, these questions, as well as potential means of addressing 
them will be discussed.  First we will focus on how ICAM1 generates some of its 
most proximal signals in ECs and how these signals may contribute to ICAM1-
dependent activation of small GTPases.  Next we will detail possible future 
directions related to the ICAM1-VE-cadherin pathway. Finally, we will conclude by 
reviewing what is known about regulation of the transcellular and paracellular 
pathways of leukocyte transmigration.  
 While it has been shown that clustering of ICAM1 leads to numerous signals 
in the endothelial cell, the exact mechanism by which ICAM1 generates these 
signals remains unclear.  The ICAM1 cytoplasmic domain is comprised of only 28 
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amino acids which are devoid of any recognizable catalytic domain.  Work presented 
here demonstrates that the cytoplasmic tail contains a proline-rich domain capable 
of mediating interaction with the SH3 domain of SGEF.  This opens the possibility 
that additional proteins may interact with ICAM1 via their SH3 domains.  Perhaps 
peptide pulldown experiments using only the proline rich domain from the ICAM1 
intracellular tail could help identify additional binding parters.   
ICAM1-mediated activation of Src kinase was one of the first signals 
attributed to ICAM1 clustering (56).  Src has subsequently been found to be one of 
the most proximal signaling molecules required for numerous signaling cascades, 
including the two discussed in this thesis (56, 65, 109).  Despite the importance of 
Src activation in ICAM-dependent signaling processes, the precise mechanism by 
which ICAM1 activates Src remains unclear.  It was shown that xanthine oxidase-
dependent reactive oxygen species (ROS) and the cytoplasmic phosphatase Src 
homology 2-containing protein-tyrosine phosphatase-2 (SHP2) are required for 
ICAM1-mediated Src activation in pulmonary microvascular endothelial cells (58).  
ICAM1 ligation by fibrinogen causes association of SHP2 with the ICAM1 
intracellular tail (119).  Interestingly, SHP2 has been shown to activate Src family 
kinases both by dephosphorylating Y530 on Src (120) or via an nonenzymatic 
mechanism wherein binding of SHP2 to the Src SH3 domain relieves an inhibitory 
intramolecular interaction within the kinase (121).  ROS are thought to inhibit 
phosphatases by oxidizing cysteine residues in the catalytic domain (122-126).  The 
fact that ROS are required for ICAM1 to activate Src suggests that perhaps the 
catalytic activity of SHP2 is not critical for Src activation in this pathway.  While we 
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have demonstrated that the activating phosphorylation of Y418 on Src is increased 
by ICAM1 clustering (Figure 8A), it is unknown whether the inhibitory 
phosphorylation of Y530 is decreased.  Perhaps this piece of data could clarify the 
role of SHP2 in activating Src.  Alternately, one could reexpress a catalytically 
inactive mutant of SHP2 in knockout or knockdown cells and test for the ability of 
ICAM1 to activate Src. 
If the mechanism of ICAM1-mediated Src activation remains somewhat 
unclear, the means by which ICAM1 regulates activity of Rho family GTPases is still 
more mysterious. Given the role of ICAM1 in activating both RhoA and RhoG, it is 
also worth examining possible mechanisms by which this is accomplished. One 
proposed mechanism involves the ERM (ezrin/radixin/moesin) family proteins, which 
are associated with the ICAM1 cytoplasmic tail (49).  It has been shown that binding 
of ERM proteins to RhoGDI (guanine nucleotide dissociation inhibitors) results in 
release of Rho proteins, allowing their activation (127).  Thus, it was suggested that 
ERM proteins associated with ICAM1 may serve to facilitate the release of RhoA 
from inhibition by RhoGDI (37).  While this process may play a role in activation of 
Rho proteins, it is also possible that guanine nucleotide exchange factors (GEFs) 
and/or GTPase activating proteins (GAPs) contribute to this regulation. 
 Here we have demonstrated that the SH3 domain of the RhoG specific GEF 
SGEF mediates its interaction with ICAM1.  Interestingly, Tim, an SH3-containing 
GEF in the same family as SGEF, is held in an inactive state by an intramolecular 
interaction between its SH3 domain and a proline-rich region found C-terminal to the 
DH domain (personal communication, M. Yohe).  It has been proposed that this 
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inhibitory intramolecular interaction could be relieved by binding of another protein to 
the SH3 domain of Tim.  In addition, recent work with Tim has shown that Tim is 
activated by Src-medidated tyrosine phosphorylation (128).  Tyrosine 
phosphorylation of Tim relieves a second inhibitory intramolecular interaction 
between the N-terminus of Tim and residues near the DH domain of Tim (128).  
Given that clustering of ICAM1 activates RhoA, it is tempting to speculate that Tim, 
which shares many similarities to SGEF plays a role in this process.  The fact that 
ICAM1 contains a proline rich domain which could potentially bind the SH3 domain 
of Tim, coupled with the ability of ICAM1 to recruit and activate Src, suggests a 
potential mechanism by which ICAM1 could relieve both inhibitory intramolecular 
interactions and thereby activate Tim.  Certainly, future studies should examine 
whether Tim is expressed in endothelial cells, whether Tim interacts with ICAM1 via 
its SH3 domain and whether Tim plays a role in ICAM1-mediated activation of RhoA.  
Technicques similar to those used in Figures 19 and 20 could be used to test for 
interactions between Tim and ICAM1 while an siRNA approach could be employed 
to test whether RhoA activation requires Tim. 
Because SGEF and Tim are in the same family and share a similar domain 
structure, it may be that these two GEFs are regulated in a similar fashion.  
Accordingly, we have found that the Src inhibitor PP2 blocks ICAM1-mediated 
activation of RhoG (Figure 18), suggesting that, as is the case with Tim, SGEF may 
be regulated by Src.  While the SGEF interacts with ICAM1 via its SH3 domain, it 
remains unknown whether or how this interaction regulates the enzymatic activity of 
SGEF.  Perhaps the most important remaining question with regard to the ICAM-
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SGEF-RhoG pathway is whether SGEF is actually required for ICAM1-mediated 
RhoG activation.  Certainly the colocalization of ICAM1, SGEF and RhoG in cells, as 
well as the fact that knockdown of SGEF and RhoG result in similar degrees of 
inhibition of docking structure formation and leukocyte TEM suggest that ICAM1 
activates RhoG via SGEF.  Performing siRNA knockdown of SGEF and then testing 
for the ability of ICAM1 to activate RhoG would confirm this.   
Also presented in this thesis is a mechanism by which ICAM1 induces 
tyrosine phosphorylation of VE-cadherin.  While we have demonstrated that both Src 
and Pyk2 are required in this pathway, there are numerous questions raised by our 
work.  For example, it is not known which kinase, Src or Pyk2, directly 
phosphorylates VE-cadherin downstream of ICAM1 engagement.  Neither is it 
known whether Src and Pyk2 act in parallel or in series in this pathway.  Pyk2 and 
Src are known to interact with one another and this interaction has been shown to 
contribute to the activation of both kinases (102-104).  However, differing reports 
regarding the interdependence of Src and Pyk2 in endothelial cells complicate 
speculation regarding the temporal regulation of these kinases in this pathway (102, 
103, 105).  One possible means of resolving this question is to inhibit Src or Pyk2 
and then test for ICAM1-mediated activation of Pyk2 or Src, respectively.  It may be 
that these kinases are activated in parallel, in which case inhibition of one kinase 
should not affect activation of the other.  Alternately they could function in series in 
which case activation of one kinase should be blocked by inhibition of the other.    
While the relationship between Src and Pyk2 is unknown, equally interesting 
are other potential players in this pathway.  There may be other intermediate signals, 
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such as reactive oxygen species, which play a role in this pathway.  It has been 
shown that ROS are required for ICAM1-mediated Src activation (58).  Thus ROS 
are likely to participate in the ICAM1-VE-cadherin pathway as well.  It is possible that 
ROS play an additional role, perhaps inactivating junctional phosphatases and 
thereby rendering the local environment more permissive for VE-cadherin 
phosphorylation.  In support of this, it has been shown that inhibition of endothelial 
phosphatases by pervanadate treatment leads to tyrosine phosphorylation of several 
adherens junctions proteins (61).  Finally, it is interesting to consider the role of other 
adhesion molecules, such as VCAM1, in the regulation of endothelial AJs during 
leukocyte TEM.  We have presented preliminary evidence that crosslinking VCAM1 
can induce tyrosine phosphorylation of VE-cadherin (Figure 6).  The finding that 
blocking ICAM1 failed to block VE-cadherin phosphorylation downstream of THP-1 
cell adhession to ECs but was able to block phosphorylation downstream from HL-
60 adhesion, suggests that VCAM1, which is bound by THP-1 cells but not HL-60 
cells, can functionally substitute for ICAM1 in this pathway (Figure 5).  Of note, 
VCAM1 engagement has been shown to activate Rac1 resulting in generation of 
reactive oxygen species, which are capable of activating Pyk2 (51, 106).  Therefore, 
engagement of VCAM1 may further activate Pyk2 downstream of leukocyte 
adhesion to ECs.  It is also interesting to note that Pyk2 phosphorylates -catenin, 
which plays a role in regulation of EC junctional stability (53).  Thus, additional 
protein components of cell-cell junctions may be affected by signals triggered by 
leukocyte adhesion.   In the future, experiments replacing anti-ICAM1 beads with 
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anti-VCAM1 beads could be used to study the similarities and/or differences 
between ICAM1 and VCAM1 signaling in this pathway. 
Given that both ICAM1 and VCAM are localized to sites of leukocyte 
adhesion and transmigration and that they mediate some of the same signals in 
ECs, it is possible that these two molecules act in concert to regulate cell-cell 
junctions during TEM.  Perhaps certain signals require contributions from both 
molecules.  It would be informative to compare the signaling properties of anti-
ICAM1 beads, anti-VCAM1 beads and beads coated with both anti-ICAM1 and anti-
VCAM1 antibodies.  To date there have been no studies examining crosstalk 
between endothelial adhesion receptors, but such studies are certainly warranted 
(87). 
Based on the studies presented in Chapter 2, we predict that modification of 
VE-cadherin plays a role specifically in paracellular transendothelial migration of 
leukocytes.  Thus the work presented here may contribute to better understanding 
the roles of the paracellular and transcellular pathways in leukocyte transmigration.  
Although reports of transcellular migration of leukocytes have been present in the 
literature for some time (129, 130), most studies have focused on the paracellular 
pathway.  This is likely due to the fact that under most conditions, the paracellular 
pathway is utilized to a greater extent than the transcellular route (12-14, 94).  
Studies in which docking structures have been visualized surrounding leukocytes 
crossing the endothelium via both the paracellular and transcellular routes have 
sparked renewed interest in the transcellular pathway of leukocyte diapedesis (12). 
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One challenge facing the field is the identification of factors that influence the 
relative utilization of these two pathways.  Several papers have begun to address 
this question.  As a result, signals proposed to be specific to either the paracellular 
or the transcellular pathways have been identified.  For example, treatment of ECs 
with IL-1 results in disruption of cell-cell junctions and is associated with an 
increase in paracellular transmigration of neutrophils (13).  This suggests that 
leukocytes are capable of determining and utilizing the path of least resistance; if 
junctions have been rendered permissive for paracellular TEM, then leukocytes 
utilize this pathway.  Additionally, it was shown that knockdown of endothelial 
caveolin blocked transcellular migration of lymphocytes but that this was 
compensated by enhanced paracellular migration (94).  What remains to be seen is 
whether specific inhibition of paracellular TEM results in compensatory transcellular 
TEM.  Work presented here suggests that complete compensation is not possible in 
the case of neutrophils because blockage of VE-cadherin phosphorylation, which 
presumably impacts only paracellular TEM, results in a ~30% inhibition of 
transmigration.  While our model states that VE-cadherin phosphorylation regulates 
only paracellular transmigration of leukocytes, we have not yet proven this directly.  
In the future it will be important to further validate our model by specifically 
examining the role of VE-cadherin and its phosphorylation status in determining the 
route of leukocyte transmigration.  Perhaps inhibition of paracellular passage of 
leukocytes by expression of non-phosphorylatable VE-cadherin mutants will cause 
enhanced transcellular TEM.  Live cell imaging of leukocytes transmigrating across 
EC monolayers expressing fluorescently labeled VE-cadherin WT and YF mutants 
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coupled with quantification of the utilization of trans- and paracellular migration 
would shed light on the possible interplay between paracellular and transcellular 
TEM.  
While some signals may be be specific for one pathway or the other, it is 
interesting to note that ICAM1 plays a role in both paracellular and transcellular 
migration.  ICAM1-positive docking structures surround all transmigrating leukocytes 
regardless of the path by which the cross the endothelium (12).  Work by Yang and 
colleagues demonstrated that levels of ICAM1 expression in ECs could affect the 
route of TEM taken by leukocytes (14).  Increasing ICAM1 expression, either by 
TNF treatment, or by stable overexpression of an ICAM-GFP construct, led to 
increased transcellular migration of neutrophils, but not T-lymphocytes (14).  In most 
cases, neutrophils were observed to transmigrate at their initial site of firm adhesion 
whether it was junctional or in the middle of the EC (14).  By contrast, T-lymphocytes 
transmigrated exclusively at junctions regardless of the site of initial adhesion.  Thus, 
ICAM1 is able to regulate the route of transmigration taken by neutrophils.  It will be 
interesting to determine whether ICAM1 induces the same signals during 
paracellular and transcellular TEM.  It is appealing to envision ICAM1 generating 
similar proximal signals, such as Src and Pyk2 kinase activation, but that these 
kinases may encounter different targets based on their localization in the cell.  In 
support of this, we show that Src and Pyk2 are recruited to sites of ICAM1 
engagement suggesting that ICAM1 can both activate and appropriately localize 
these molecules.  Thus, kinases activated by ICAM1 engaged by leukocytes 
undergoing paracellular TEM may target junctions while these same signals may 
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affect different targets during transcellular TEM.  For example, others have shown 
that Src-mediated cortactin phosphorylation downstream from ICAM1 engagement 
was critical for paracellular TEM of neutrophils, thus cortactin may be another 
junction-specific target (59, 65).  The differential signaling involved in transcellular 
and paracellular TEM will likely be a topic of intensive research in years to come.    
We and others have shown that ICAM1 is involved in numerous aspects of 
leukocyte transmigration across the endothelium including firm adhesion, migration 
on the surface of the endothelium, disassembly of endothelial junctions and the 
formation of docking structures (Figure 23).  Despite this, relatively little is known 
about precisely how ICAM1 mediates its effects in endothelial cells.  In this thesis we 
have chracterized two novel signaling pathways initiated by clustering of ICAM1 in 
leukocyte TEM.  One, the phosphorylation of VE-cadherin, likely contributes to 
leukocyte-mediated disruption of endothelial junctions while the other, activation of 
RhoG, is required for the formation of docking structures.  In spite of its prominent 
role in TEM and inflammation and the fact that inhibition of ICAM1 has been 
proposed as a means of reducing inflammation in diseases ranging from multiple 
sclerosis to myocardial infarction (69, 131), anti-ICAM1 antibodies currently 
represent the only means of blocking ICAM1 function in vivo. Antibody-based 
therapies have numerous drawbacks including high costs, and requiring intravenous 
administration.  The work presented in this thesis has identified several potential 
therapeutic targets that could block ICAM1-mediated signaling and leukocyte 
transendothelial migration.  These are discussed briefly below. 
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The ICAM1 tail region may contain several potential regions that could provide 
targets for therapy.  One example is provided by SGEF, which interacts with a 9 
amino acid region of the ICAM1 cytoplasmic tail.  It is possible that an even smaller 
region is required, but this has not yet been studied by serial mutation of the ICAM1 
cytoplasmic tail.  If SGEF interaction with ICAM1 is required for efficient leukocyte 
TEM, perhaps a small molecule could be designed to inhibit this interaction.  
Alternately, it is possible that a small molecule that mimics the putative inhibitory 
intramolecular interactions that regulate SGEF could be used to directly target 
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SGEF, which we have shown to be required for efficient leukocyte TEM.  Clearly, 
further study of SGEF regulation is required to justify this strategy. 
 Of note, Src has been shown to be required for many ICAM1-dependent 
signaling functions including the phosphorylation of cortactin (56, 65), the activation 
of RhoG, and the phosphorylation of VE-cadherin.  Interestingly, numerous 
compounds that target Src are in development for use as cancer treatments.  
Perhaps these drugs, or modified derivatives could also be used as inhibitors of 
inflammation.  Given the role of Src in many biological processes, possible side 
effects of Src inhibition represent a legitimate concern.  However, because the 
endothelium is in direct contact with the blood, it may be that lower doses could have 
therapeutic effects on ECs without reaching significant concentrations in other 
tissues.  If this proved to be the case, the side effects of Src inhibition might be 
reduced.  It would be interesting indeed to look at the effects of these Src inhibitors 
in mouse models of multiple sclerosis or myocardial infarction.  Hopefully this work 
will be forthcoming in the next few years.  
With this work we have begun to explain the mechanisms behind ICAM1-
mediated junctional disruption and docking structure formation and in so doing have 
identified potential targets for anti-inflammatory treatments.  It is my hope that these 
data, as well as the techniques, constructs, and ideas presented here have layed the 
groundwork for future research into the functions of ICAM1 in TEM.  I feel that, given 
the established role of inflammation in human disease that better understanding the 
obligate step of leukocyte transmigration is an important and worthy focus for future 
studies. 
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